#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Regional homogeneity changes between heroin relapse and non-relapse patients under methadone maintenance treatment: a resting-state fMRI study
#Text=Background
#Text=Methadone maintenance treatment (MMT) is recognized as one of the most effective treatments for heroin addiction but its effect is dimmed by the high incidence of heroin relapse.
1-1	0-8	Regional	_	
1-2	9-20	homogeneity	_	
1-3	21-28	changes	_	
1-4	29-36	between	_	
1-5	37-43	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-6	44-51	relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-7	52-55	and	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-8	56-67	non-relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-9	68-76	patients	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-10	77-82	under	_	
1-11	83-92	methadone	_	
1-12	93-104	maintenance	_	
1-13	105-114	treatment	_	
1-14	114-115	:	_	
1-15	116-117	a	_	
1-16	118-131	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-17	132-136	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-18	137-142	study	_	
1-19	143-153	Background	_	
1-20	154-163	Methadone	_	
1-21	164-175	maintenance	_	
1-22	176-185	treatment	_	
1-23	186-187	(	_	
1-24	187-190	MMT	_	
1-25	190-191	)	_	
1-26	192-194	is	_	
1-27	195-205	recognized	_	
1-28	206-208	as	_	
1-29	209-212	one	_	
1-30	213-215	of	_	
1-31	216-219	the	_	
1-32	220-224	most	_	
1-33	225-234	effective	_	
1-34	235-245	treatments	_	
1-35	246-249	for	_	
1-36	250-256	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
1-37	257-266	addiction	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[3]	
1-38	267-270	but	_	
1-39	271-274	its	_	
1-40	275-281	effect	_	
1-41	282-284	is	_	
1-42	285-291	dimmed	_	
1-43	292-294	by	_	
1-44	295-298	the	_	
1-45	299-303	high	_	
1-46	304-313	incidence	_	
1-47	314-316	of	_	
1-48	317-323	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
1-49	324-331	relapse	_	
1-50	331-332	.	_	

#Text=However, underlying neurobiology mechanism of heroin relapse under MMT is still largely unknown.
2-1	333-340	However	_	
2-2	340-341	,	_	
2-3	342-352	underlying	_	
2-4	353-365	neurobiology	_	
2-5	366-375	mechanism	_	
2-6	376-378	of	_	
2-7	379-385	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
2-8	386-393	relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
2-9	394-399	under	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
2-10	400-403	MMT	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
2-11	404-406	is	_	
2-12	407-412	still	_	
2-13	413-420	largely	_	
2-14	421-428	unknown	_	
2-15	428-429	.	_	

#Text=Here, we took advantage of a resting-state fMRI technique by analysis of regional homogeneity (ReHo), and tried to explore the difference of brain function between heroin relapsers and non-relapsers in MMT.
3-1	430-434	Here	_	
3-2	434-435	,	_	
3-3	436-438	we	_	
3-4	439-443	took	_	
3-5	444-453	advantage	_	
3-6	454-456	of	_	
3-7	457-458	a	_	
3-8	459-472	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
3-9	473-477	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
3-10	478-487	technique	_	
3-11	488-490	by	_	
3-12	491-499	analysis	_	
3-13	500-502	of	_	
3-14	503-511	regional	_	
3-15	512-523	homogeneity	_	
3-16	524-525	(	_	
3-17	525-529	ReHo	_	
3-18	529-530	)	_	
3-19	530-531	,	_	
3-20	532-535	and	_	
3-21	536-541	tried	_	
3-22	542-544	to	_	
3-23	545-552	explore	_	
3-24	553-556	the	_	
3-25	557-567	difference	_	
3-26	568-570	of	_	
3-27	571-576	brain	_	
3-28	577-585	function	_	
3-29	586-593	between	_	
3-30	594-600	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[6]	
3-31	601-610	relapsers	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[6]	
3-32	611-614	and	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[6]	
3-33	615-628	non-relapsers	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[6]	
3-34	629-631	in	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[6]	
3-35	632-635	MMT	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[6]	
3-36	635-636	.	_	

#Text=Methods
#Text=Forty MMT patients were included and received a 12-month follow-up.
4-1	637-644	Methods	_	
4-2	645-650	Forty	_	
4-3	651-654	MMT	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[7]	
4-4	655-663	patients	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[7]	
4-5	664-668	were	_	
4-6	669-677	included	_	
4-7	678-681	and	_	
4-8	682-690	received	_	
4-9	691-692	a	_	
4-10	693-695	12	_	
4-11	695-696	-	_	
4-12	696-701	month	_	
4-13	702-711	follow-up	_	
4-14	711-712	.	_	

#Text=All patients were given baseline resting-state fMRI scans by using a 3.0 T GE Signa Excite HD whole-body MRI system.
5-1	713-716	All	_	
5-2	717-725	patients	_	
5-3	726-730	were	_	
5-4	731-736	given	_	
5-5	737-745	baseline	_	
5-6	746-759	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]	
5-7	760-764	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]	
5-8	765-770	scans	_	
5-9	771-773	by	_	
5-10	774-779	using	_	
5-11	780-781	a	_	
5-12	782-785	3.0	_	
5-13	785-786	 	_	
5-14	786-787	T	_	
5-15	788-790	GE	_	
5-16	791-796	Signa	_	
5-17	797-803	Excite	_	
5-18	804-806	HD	_	
5-19	807-817	whole-body	_	
5-20	818-821	MRI	_	
5-21	822-828	system	_	
5-22	828-829	.	_	

#Text=Monthly self-report and urine test were used to assess heroin relapse or non-relapse.
6-1	830-837	Monthly	_	
6-2	838-849	self-report	_	
6-3	850-853	and	_	
6-4	854-859	urine	_	
6-5	860-864	test	_	
6-6	865-869	were	_	
6-7	870-874	used	_	
6-8	875-877	to	_	
6-9	878-884	assess	_	
6-10	885-891	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[9]	
6-11	892-899	relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[9]	
6-12	900-902	or	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[9]	
6-13	903-914	non-relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[9]	
6-14	914-915	.	_	

#Text=Subjective craving was measured with visual analog scale.
7-1	916-926	Subjective	_	
7-2	927-934	craving	_	
7-3	935-938	was	_	
7-4	939-947	measured	_	
7-5	948-952	with	_	
7-6	953-959	visual	_	
7-7	960-966	analog	_	
7-8	967-972	scale	_	
7-9	972-973	.	_	

#Text=The correlation between ReHo and the degree of heroin relapse was analyzed.
8-1	974-977	The	_	
8-2	978-989	correlation	_	
8-3	990-997	between	_	
8-4	998-1002	ReHo	_	
8-5	1003-1006	and	_	
8-6	1007-1010	the	_	
8-7	1011-1017	degree	_	
8-8	1018-1020	of	_	
8-9	1021-1027	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[10]	
8-10	1028-1035	relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[10]	
8-11	1036-1039	was	_	
8-12	1040-1048	analyzed	_	
8-13	1048-1049	.	_	

#Text=Results
#Text=Compared with the non-relapsers, ReHo values were increased in the bilateral medial orbitofrontal cortex, right caudate, and right cerebellum of the heroin relapsers while those in the left parahippocampal gyrus, left middle temporal gyrus, right lingual gyrus, and precuneus were decreased in heroin relapsers.
9-1	1050-1057	Results	_	
9-2	1058-1066	Compared	_	
9-3	1067-1071	with	_	
9-4	1072-1075	the	_	
9-5	1076-1089	non-relapsers	_	
9-6	1089-1090	,	_	
9-7	1091-1095	ReHo	_	
9-8	1096-1102	values	_	
9-9	1103-1107	were	_	
9-10	1108-1117	increased	_	
9-11	1118-1120	in	_	
9-12	1121-1124	the	_	
9-13	1125-1134	bilateral	_	
9-14	1135-1141	medial	_	
9-15	1142-1155	orbitofrontal	_	
9-16	1156-1162	cortex	_	
9-17	1162-1163	,	_	
9-18	1164-1169	right	_	
9-19	1170-1177	caudate	_	
9-20	1177-1178	,	_	
9-21	1179-1182	and	_	
9-22	1183-1188	right	_	
9-23	1189-1199	cerebellum	_	
9-24	1200-1202	of	_	
9-25	1203-1206	the	_	
9-26	1207-1213	heroin	_	
9-27	1214-1223	relapsers	_	
9-28	1224-1229	while	_	
9-29	1230-1235	those	_	
9-30	1236-1238	in	_	
9-31	1239-1242	the	_	
9-32	1243-1247	left	_	
9-33	1248-1263	parahippocampal	_	
9-34	1264-1269	gyrus	_	
9-35	1269-1270	,	_	
9-36	1271-1275	left	_	
9-37	1276-1282	middle	_	
9-38	1283-1291	temporal	_	
9-39	1292-1297	gyrus	_	
9-40	1297-1298	,	_	
9-41	1299-1304	right	_	
9-42	1305-1312	lingual	_	
9-43	1313-1318	gyrus	_	
9-44	1318-1319	,	_	
9-45	1320-1323	and	_	
9-46	1324-1333	precuneus	_	
9-47	1334-1338	were	_	
9-48	1339-1348	decreased	_	
9-49	1349-1351	in	_	
9-50	1352-1358	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[11]	
9-51	1359-1368	relapsers	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[11]	
9-52	1368-1369	.	_	

#Text=Importantly, altered ReHo in the right caudate were positively correlated with heroin relapse rates or subjective craving response.
10-1	1370-1381	Importantly	_	
10-2	1381-1382	,	_	
10-3	1383-1390	altered	_	
10-4	1391-1395	ReHo	_	
10-5	1396-1398	in	_	
10-6	1399-1402	the	_	
10-7	1403-1408	right	_	
10-8	1409-1416	caudate	_	
10-9	1417-1421	were	_	
10-10	1422-1432	positively	_	
10-11	1433-1443	correlated	_	
10-12	1444-1448	with	_	
10-13	1449-1455	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[12]	
10-14	1456-1463	relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[12]	
10-15	1464-1469	rates	_	
10-16	1470-1472	or	_	
10-17	1473-1483	subjective	_	
10-18	1484-1491	craving	_	
10-19	1492-1500	response	_	
10-20	1500-1501	.	_	

#Text=Conclusions
#Text=Using the resting-state fMRI technique by analysis of ReHo, we provided the first resting-state fMRI evidence that right caudate may serve as a potential biomarker for heroin relapse prediction and also as a promising target for reducing relapse risk.
11-1	1502-1513	Conclusions	_	
11-2	1514-1519	Using	_	
11-3	1520-1523	the	_	
11-4	1524-1537	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[13]	
11-5	1538-1542	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[13]	
11-6	1543-1552	technique	_	
11-7	1553-1555	by	_	
11-8	1556-1564	analysis	_	
11-9	1565-1567	of	_	
11-10	1568-1572	ReHo	_	
11-11	1572-1573	,	_	
11-12	1574-1576	we	_	
11-13	1577-1585	provided	_	
11-14	1586-1589	the	_	
11-15	1590-1595	first	_	
11-16	1596-1609	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[14]	
11-17	1610-1614	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[14]	
11-18	1615-1623	evidence	_	
11-19	1624-1628	that	_	
11-20	1629-1634	right	_	
11-21	1635-1642	caudate	_	
11-22	1643-1646	may	_	
11-23	1647-1652	serve	_	
11-24	1653-1655	as	_	
11-25	1656-1657	a	_	
11-26	1658-1667	potential	_	
11-27	1668-1677	biomarker	_	
11-28	1678-1681	for	_	
11-29	1682-1688	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[15]	
11-30	1689-1696	relapse	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[15]	
11-31	1697-1707	prediction	_	
11-32	1708-1711	and	_	
11-33	1712-1716	also	_	
11-34	1717-1719	as	_	
11-35	1720-1721	a	_	
11-36	1722-1731	promising	_	
11-37	1732-1738	target	_	
11-38	1739-1742	for	_	
11-39	1743-1751	reducing	_	
11-40	1752-1759	relapse	_	
11-41	1760-1764	risk	_	
11-42	1764-1765	.	_	

#Text=Background
#Text=Drug addiction is a kind of chronic cerebral dysfunction.
12-1	1766-1776	Background	_	
12-2	1777-1781	Drug	_	
12-3	1782-1791	addiction	_	
12-4	1792-1794	is	_	
12-5	1795-1796	a	_	
12-6	1797-1801	kind	_	
12-7	1802-1804	of	_	
12-8	1805-1812	chronic	_	
12-9	1813-1821	cerebral	_	
12-10	1822-1833	dysfunction	_	
12-11	1833-1834	.	_	

#Text=Unlike cocaine and cannabis popular in foreign countries, heroin is popular in China.
13-1	1835-1841	Unlike	_	
13-2	1842-1849	cocaine	_	
13-3	1850-1853	and	_	
13-4	1854-1862	cannabis	_	
13-5	1863-1870	popular	_	
13-6	1871-1873	in	_	
13-7	1874-1881	foreign	_	
13-8	1882-1891	countries	_	
13-9	1891-1892	,	_	
13-10	1893-1899	heroin	_	
13-11	1900-1902	is	_	
13-12	1903-1910	popular	_	
13-13	1911-1913	in	_	
13-14	1914-1919	China	_	
13-15	1919-1920	.	_	

#Text=Compared with cocaine and cannabis, heroin causes more tolerance and addiction.
14-1	1921-1929	Compared	_	
14-2	1930-1934	with	_	
14-3	1935-1942	cocaine	_	
14-4	1943-1946	and	_	
14-5	1947-1955	cannabis	_	
14-6	1955-1956	,	_	
14-7	1957-1963	heroin	_	
14-8	1964-1970	causes	_	
14-9	1971-1975	more	_	
14-10	1976-1985	tolerance	_	
14-11	1986-1989	and	_	
14-12	1990-1999	addiction	_	
14-13	1999-2000	.	_	

#Text=More seriously, once addicted with heroin, it is hard to abstinence.
15-1	2001-2005	More	_	
15-2	2006-2015	seriously	_	
15-3	2015-2016	,	_	
15-4	2017-2021	once	_	
15-5	2022-2030	addicted	_	
15-6	2031-2035	with	_	
15-7	2036-2042	heroin	_	
15-8	2042-2043	,	_	
15-9	2044-2046	it	_	
15-10	2047-2049	is	_	
15-11	2050-2054	hard	_	
15-12	2055-2057	to	_	
15-13	2058-2068	abstinence	_	
15-14	2068-2069	.	_	

#Text=Currently, methadone maintenance treatment (MMT) is a main strategy for the treatment of heroin addiction.
16-1	2070-2079	Currently	_	
16-2	2079-2080	,	_	
16-3	2081-2090	methadone	_	
16-4	2091-2102	maintenance	_	
16-5	2103-2112	treatment	_	
16-6	2113-2114	(	_	
16-7	2114-2117	MMT	_	
16-8	2117-2118	)	_	
16-9	2119-2121	is	_	
16-10	2122-2123	a	_	
16-11	2124-2128	main	_	
16-12	2129-2137	strategy	_	
16-13	2138-2141	for	_	
16-14	2142-2145	the	_	
16-15	2146-2155	treatment	_	
16-16	2156-2158	of	_	
16-17	2159-2165	heroin	_	
16-18	2166-2175	addiction	_	
16-19	2175-2176	.	_	

#Text=However, unfortunately, MMT cannot completely solve the problem of heroin abuse due to the fact that the relapse rate still remained high under MMT.
17-1	2177-2184	However	_	
17-2	2184-2185	,	_	
17-3	2186-2199	unfortunately	_	
17-4	2199-2200	,	_	
17-5	2201-2204	MMT	_	
17-6	2205-2211	cannot	_	
17-7	2212-2222	completely	_	
17-8	2223-2228	solve	_	
17-9	2229-2232	the	_	
17-10	2233-2240	problem	_	
17-11	2241-2243	of	_	
17-12	2244-2250	heroin	_	
17-13	2251-2256	abuse	_	
17-14	2257-2260	due	_	
17-15	2261-2263	to	_	
17-16	2264-2267	the	_	
17-17	2268-2272	fact	_	
17-18	2273-2277	that	_	
17-19	2278-2281	the	_	
17-20	2282-2289	relapse	_	
17-21	2290-2294	rate	_	
17-22	2295-2300	still	_	
17-23	2301-2309	remained	_	
17-24	2310-2314	high	_	
17-25	2315-2320	under	_	
17-26	2321-2324	MMT	_	
17-27	2324-2325	.	_	

#Text=Apart from psychological and social factors, many researchers believed that neurobiological factors were also involved in heroin addiction and relapse.
18-1	2326-2331	Apart	_	
18-2	2332-2336	from	_	
18-3	2337-2350	psychological	_	
18-4	2351-2354	and	_	
18-5	2355-2361	social	_	
18-6	2362-2369	factors	_	
18-7	2369-2370	,	_	
18-8	2371-2375	many	_	
18-9	2376-2387	researchers	_	
18-10	2388-2396	believed	_	
18-11	2397-2401	that	_	
18-12	2402-2417	neurobiological	_	
18-13	2418-2425	factors	_	
18-14	2426-2430	were	_	
18-15	2431-2435	also	_	
18-16	2436-2444	involved	_	
18-17	2445-2447	in	_	
18-18	2448-2454	heroin	_	
18-19	2455-2464	addiction	_	
18-20	2465-2468	and	_	
18-21	2469-2476	relapse	_	
18-22	2476-2477	.	_	

#Text=In recent years, a body of studies have been making the attempt on neural circuits and brain functions in heroin addiction by using resting-state fMRI method.
19-1	2478-2480	In	_	
19-2	2481-2487	recent	_	
19-3	2488-2493	years	_	
19-4	2493-2494	,	_	
19-5	2495-2496	a	_	
19-6	2497-2501	body	_	
19-7	2502-2504	of	_	
19-8	2505-2512	studies	_	
19-9	2513-2517	have	_	
19-10	2518-2522	been	_	
19-11	2523-2529	making	_	
19-12	2530-2533	the	_	
19-13	2534-2541	attempt	_	
19-14	2542-2544	on	_	
19-15	2545-2551	neural	_	
19-16	2552-2560	circuits	_	
19-17	2561-2564	and	_	
19-18	2565-2570	brain	_	
19-19	2571-2580	functions	_	
19-20	2581-2583	in	_	
19-21	2584-2590	heroin	_	
19-22	2591-2600	addiction	_	
19-23	2601-2603	by	_	
19-24	2604-2609	using	_	
19-25	2610-2623	resting-state	_	
19-26	2624-2628	fMRI	_	
19-27	2629-2635	method	_	
19-28	2635-2636	.	_	

#Text=By comparing heroin addicts with healthy controls, researchers revealed a heroin-related organization pattern.
20-1	2637-2639	By	_	
20-2	2640-2649	comparing	_	
20-3	2650-2656	heroin	_	
20-4	2657-2664	addicts	_	
20-5	2665-2669	with	_	
20-6	2670-2677	healthy	_	
20-7	2678-2686	controls	_	
20-8	2686-2687	,	_	
20-9	2688-2699	researchers	_	
20-10	2700-2708	revealed	_	
20-11	2709-2710	a	_	
20-12	2711-2725	heroin-related	_	
20-13	2726-2738	organization	_	
20-14	2739-2746	pattern	_	
20-15	2746-2747	.	_	

#Text=For instance, Ma et al. observed the enhanced functional connectivity between the nucleus accumbens and the ventral cingulate cortex, the orbitofrontal cortex (OFC), or the amygdala whereas the decreased functional connectivity between the anterior cingulate and the prefrontal cortex or the OFC was evident in heroin addicts.
21-1	2748-2751	For	_	
21-2	2752-2760	instance	_	
21-3	2760-2761	,	_	
21-4	2762-2764	Ma	_	
21-5	2765-2767	et	_	
21-6	2768-2770	al	_	
21-7	2770-2771	.	_	
21-8	2772-2780	observed	_	
21-9	2781-2784	the	_	
21-10	2785-2793	enhanced	_	
21-11	2794-2804	functional	_	
21-12	2805-2817	connectivity	_	
21-13	2818-2825	between	_	
21-14	2826-2829	the	_	
21-15	2830-2837	nucleus	_	
21-16	2838-2847	accumbens	_	
21-17	2848-2851	and	_	
21-18	2852-2855	the	_	
21-19	2856-2863	ventral	_	
21-20	2864-2873	cingulate	_	
21-21	2874-2880	cortex	_	
21-22	2880-2881	,	_	
21-23	2882-2885	the	_	
21-24	2886-2899	orbitofrontal	_	
21-25	2900-2906	cortex	_	
21-26	2907-2908	(	_	
21-27	2908-2911	OFC	_	
21-28	2911-2912	)	_	
21-29	2912-2913	,	_	
21-30	2914-2916	or	_	
21-31	2917-2920	the	_	
21-32	2921-2929	amygdala	_	
21-33	2930-2937	whereas	_	
21-34	2938-2941	the	_	
21-35	2942-2951	decreased	_	
21-36	2952-2962	functional	_	
21-37	2963-2975	connectivity	_	
21-38	2976-2983	between	_	
21-39	2984-2987	the	_	
21-40	2988-2996	anterior	_	
21-41	2997-3006	cingulate	_	
21-42	3007-3010	and	_	
21-43	3011-3014	the	_	
21-44	3015-3025	prefrontal	_	
21-45	3026-3032	cortex	_	
21-46	3033-3035	or	_	
21-47	3036-3039	the	_	
21-48	3040-3043	OFC	_	
21-49	3044-3047	was	_	
21-50	3048-3055	evident	_	
21-51	3056-3058	in	_	
21-52	3059-3065	heroin	_	
21-53	3066-3073	addicts	_	
21-54	3073-3074	.	_	

#Text=With the graph theory analysis, Liu et al. found dysfunctional connectivity in the anterior cingulate cortex, amygdala, insula, hippocampus, nucleus accumbens, prefrontal cortex, supplementary motor area, and ventral striatum in chronic heroin users.
22-1	3075-3079	With	_	
22-2	3080-3083	the	_	
22-3	3084-3089	graph	_	
22-4	3090-3096	theory	_	
22-5	3097-3105	analysis	_	
22-6	3105-3106	,	_	
22-7	3107-3110	Liu	_	
22-8	3111-3113	et	_	
22-9	3114-3116	al	_	
22-10	3116-3117	.	_	
22-11	3118-3123	found	_	
22-12	3124-3137	dysfunctional	_	
22-13	3138-3150	connectivity	_	
22-14	3151-3153	in	_	
22-15	3154-3157	the	_	
22-16	3158-3166	anterior	_	
22-17	3167-3176	cingulate	_	
22-18	3177-3183	cortex	_	
22-19	3183-3184	,	_	
22-20	3185-3193	amygdala	_	
22-21	3193-3194	,	_	
22-22	3195-3201	insula	_	
22-23	3201-3202	,	_	
22-24	3203-3214	hippocampus	_	
22-25	3214-3215	,	_	
22-26	3216-3223	nucleus	_	
22-27	3224-3233	accumbens	_	
22-28	3233-3234	,	_	
22-29	3235-3245	prefrontal	_	
22-30	3246-3252	cortex	_	
22-31	3252-3253	,	_	
22-32	3254-3267	supplementary	_	
22-33	3268-3273	motor	_	
22-34	3274-3278	area	_	
22-35	3278-3279	,	_	
22-36	3280-3283	and	_	
22-37	3284-3291	ventral	_	
22-38	3292-3300	striatum	_	
22-39	3301-3303	in	_	
22-40	3304-3311	chronic	_	
22-41	3312-3318	heroin	_	
22-42	3319-3324	users	_	
22-43	3324-3325	.	_	

#Text=Therefore, resting-state fMRI method could not only reveal the abnormal baseline function in heroin users at the resting state, but also show the abnormal functional connectivity of two remote areas.
23-1	3326-3335	Therefore	_	
23-2	3335-3336	,	_	
23-3	3337-3350	resting-state	_	
23-4	3351-3355	fMRI	_	
23-5	3356-3362	method	_	
23-6	3363-3368	could	_	
23-7	3369-3372	not	_	
23-8	3373-3377	only	_	
23-9	3378-3384	reveal	_	
23-10	3385-3388	the	_	
23-11	3389-3397	abnormal	_	
23-12	3398-3406	baseline	_	
23-13	3407-3415	function	_	
23-14	3416-3418	in	_	
23-15	3419-3425	heroin	_	
23-16	3426-3431	users	_	
23-17	3432-3434	at	_	
23-18	3435-3438	the	_	
23-19	3439-3446	resting	_	
23-20	3447-3452	state	_	
23-21	3452-3453	,	_	
23-22	3454-3457	but	_	
23-23	3458-3462	also	_	
23-24	3463-3467	show	_	
23-25	3468-3471	the	_	
23-26	3472-3480	abnormal	_	
23-27	3481-3491	functional	_	
23-28	3492-3504	connectivity	_	
23-29	3505-3507	of	_	
23-30	3508-3511	two	_	
23-31	3512-3518	remote	_	
23-32	3519-3524	areas	_	
23-33	3524-3525	.	_	

#Text=Recently, the regional homogeneity (ReHo) method has been developed to analyse the similarities or coherence of intraregional spontaneous low-frequency (<0.08 Hz) blood oxygenation level-dependent signal fluctuations in voxel-wise analysis across the whole brain.
24-1	3526-3534	Recently	_	
24-2	3534-3535	,	_	
24-3	3536-3539	the	_	
24-4	3540-3548	regional	_	
24-5	3549-3560	homogeneity	_	
24-6	3561-3562	(	_	
24-7	3562-3566	ReHo	_	
24-8	3566-3567	)	_	
24-9	3568-3574	method	_	
24-10	3575-3578	has	_	
24-11	3579-3583	been	_	
24-12	3584-3593	developed	_	
24-13	3594-3596	to	_	
24-14	3597-3604	analyse	_	
24-15	3605-3608	the	_	
24-16	3609-3621	similarities	_	
24-17	3622-3624	or	_	
24-18	3625-3634	coherence	_	
24-19	3635-3637	of	_	
24-20	3638-3651	intraregional	_	
24-21	3652-3663	spontaneous	_	
24-22	3664-3677	low-frequency	_	
24-23	3678-3679	(	_	
24-24	3679-3680	<	_	
24-25	3680-3684	0.08	_	
24-26	3684-3685	 	_	
24-27	3685-3687	Hz	_	
24-28	3687-3688	)	_	
24-29	3689-3694	blood	_	
24-30	3695-3706	oxygenation	_	
24-31	3707-3722	level-dependent	_	
24-32	3723-3729	signal	_	
24-33	3730-3742	fluctuations	_	
24-34	3743-3745	in	_	
24-35	3746-3756	voxel-wise	_	
24-36	3757-3765	analysis	_	
24-37	3766-3772	across	_	
24-38	3773-3776	the	_	
24-39	3777-3782	whole	_	
24-40	3783-3788	brain	_	
24-41	3788-3789	.	_	

#Text=Due to independence of the onset time of stimulus, this method is useful for resting-state fMRI data analysis to indicate the resting state in a given brain region.
25-1	3790-3793	Due	_	
25-2	3794-3796	to	_	
25-3	3797-3809	independence	_	
25-4	3810-3812	of	_	
25-5	3813-3816	the	_	
25-6	3817-3822	onset	_	
25-7	3823-3827	time	_	
25-8	3828-3830	of	_	
25-9	3831-3839	stimulus	_	
25-10	3839-3840	,	_	
25-11	3841-3845	this	_	
25-12	3846-3852	method	_	
25-13	3853-3855	is	_	
25-14	3856-3862	useful	_	
25-15	3863-3866	for	_	
25-16	3867-3880	resting-state	_	
25-17	3881-3885	fMRI	_	
25-18	3886-3890	data	_	
25-19	3891-3899	analysis	_	
25-20	3900-3902	to	_	
25-21	3903-3911	indicate	_	
25-22	3912-3915	the	_	
25-23	3916-3923	resting	_	
25-24	3924-3929	state	_	
25-25	3930-3932	in	_	
25-26	3933-3934	a	_	
25-27	3935-3940	given	_	
25-28	3941-3946	brain	_	
25-29	3947-3953	region	_	
25-30	3953-3954	.	_	

#Text=It has been used to investigate the functional modulations in the resting state in healthy aging subjects and in patients with Alzheimer disease, Parkinson disease, schizophrenia, and neuromyelitis optica.
26-1	3955-3957	It	_	
26-2	3958-3961	has	_	
26-3	3962-3966	been	_	
26-4	3967-3971	used	_	
26-5	3972-3974	to	_	
26-6	3975-3986	investigate	_	
26-7	3987-3990	the	_	
26-8	3991-4001	functional	_	
26-9	4002-4013	modulations	_	
26-10	4014-4016	in	_	
26-11	4017-4020	the	_	
26-12	4021-4028	resting	_	
26-13	4029-4034	state	_	
26-14	4035-4037	in	_	
26-15	4038-4045	healthy	_	
26-16	4046-4051	aging	_	
26-17	4052-4060	subjects	_	
26-18	4061-4064	and	_	
26-19	4065-4067	in	_	
26-20	4068-4076	patients	_	
26-21	4077-4081	with	_	
26-22	4082-4091	Alzheimer	_	
26-23	4092-4099	disease	_	
26-24	4099-4100	,	_	
26-25	4101-4110	Parkinson	_	
26-26	4111-4118	disease	_	
26-27	4118-4119	,	_	
26-28	4120-4133	schizophrenia	_	
26-29	4133-4134	,	_	
26-30	4135-4138	and	_	
26-31	4139-4152	neuromyelitis	_	
26-32	4153-4159	optica	_	
26-33	4159-4160	.	_	

#Text=Importantly, using this method, Qiu et al. revealed that ReHo values in the bilateral OFC and medial thalamic of heroin addicts were lower than that in healthy subjects.
27-1	4161-4172	Importantly	_	
27-2	4172-4173	,	_	
27-3	4174-4179	using	_	
27-4	4180-4184	this	_	
27-5	4185-4191	method	_	
27-6	4191-4192	,	_	
27-7	4193-4196	Qiu	_	
27-8	4197-4199	et	_	
27-9	4200-4202	al	_	
27-10	4202-4203	.	_	
27-11	4204-4212	revealed	_	
27-12	4213-4217	that	_	
27-13	4218-4222	ReHo	_	
27-14	4223-4229	values	_	
27-15	4230-4232	in	_	
27-16	4233-4236	the	_	
27-17	4237-4246	bilateral	_	
27-18	4247-4250	OFC	_	
27-19	4251-4254	and	_	
27-20	4255-4261	medial	_	
27-21	4262-4270	thalamic	_	
27-22	4271-4273	of	_	
27-23	4274-4280	heroin	_	
27-24	4281-4288	addicts	_	
27-25	4289-4293	were	_	
27-26	4294-4299	lower	_	
27-27	4300-4304	than	_	
27-28	4305-4309	that	_	
27-29	4310-4312	in	_	
27-30	4313-4320	healthy	_	
27-31	4321-4329	subjects	_	
27-32	4329-4330	.	_	

#Text=However, at present we still lacked the knowledge about the changes of ReHo between heroin relapse and non-relapse patients receiving MMT.
28-1	4331-4338	However	_	
28-2	4338-4339	,	_	
28-3	4340-4342	at	_	
28-4	4343-4350	present	_	
28-5	4351-4353	we	_	
28-6	4354-4359	still	_	
28-7	4360-4366	lacked	_	
28-8	4367-4370	the	_	
28-9	4371-4380	knowledge	_	
28-10	4381-4386	about	_	
28-11	4387-4390	the	_	
28-12	4391-4398	changes	_	
28-13	4399-4401	of	_	
28-14	4402-4406	ReHo	_	
28-15	4407-4414	between	_	
28-16	4415-4421	heroin	_	
28-17	4422-4429	relapse	_	
28-18	4430-4433	and	_	
28-19	4434-4445	non-relapse	_	
28-20	4446-4454	patients	_	
28-21	4455-4464	receiving	_	
28-22	4465-4468	MMT	_	
28-23	4468-4469	.	_	

#Text=In the present study, we included forty heroin addicts, and by using the resting-state fMRI technique to investigate the difference of resting-state brain function between heroin relapser and non-relapser in MMT patients by analysis of ReHo changes, trying to provide a further insight into the neurobiological mechanism underlying heroin relapse in MMT patients.
29-1	4470-4472	In	_	
29-2	4473-4476	the	_	
29-3	4477-4484	present	_	
29-4	4485-4490	study	_	
29-5	4490-4491	,	_	
29-6	4492-4494	we	_	
29-7	4495-4503	included	_	
29-8	4504-4509	forty	_	
29-9	4510-4516	heroin	_	
29-10	4517-4524	addicts	_	
29-11	4524-4525	,	_	
29-12	4526-4529	and	_	
29-13	4530-4532	by	_	
29-14	4533-4538	using	_	
29-15	4539-4542	the	_	
29-16	4543-4556	resting-state	_	
29-17	4557-4561	fMRI	_	
29-18	4562-4571	technique	_	
29-19	4572-4574	to	_	
29-20	4575-4586	investigate	_	
29-21	4587-4590	the	_	
29-22	4591-4601	difference	_	
29-23	4602-4604	of	_	
29-24	4605-4618	resting-state	_	
29-25	4619-4624	brain	_	
29-26	4625-4633	function	_	
29-27	4634-4641	between	_	
29-28	4642-4648	heroin	_	
29-29	4649-4657	relapser	_	
29-30	4658-4661	and	_	
29-31	4662-4674	non-relapser	_	
29-32	4675-4677	in	_	
29-33	4678-4681	MMT	_	
29-34	4682-4690	patients	_	
29-35	4691-4693	by	_	
29-36	4694-4702	analysis	_	
29-37	4703-4705	of	_	
29-38	4706-4710	ReHo	_	
29-39	4711-4718	changes	_	
29-40	4718-4719	,	_	
29-41	4720-4726	trying	_	
29-42	4727-4729	to	_	
29-43	4730-4737	provide	_	
29-44	4738-4739	a	_	
29-45	4740-4747	further	_	
29-46	4748-4755	insight	_	
29-47	4756-4760	into	_	
29-48	4761-4764	the	_	
29-49	4765-4780	neurobiological	_	
29-50	4781-4790	mechanism	_	
29-51	4791-4801	underlying	_	
29-52	4802-4808	heroin	_	
29-53	4809-4816	relapse	_	
29-54	4817-4819	in	_	
29-55	4820-4823	MMT	_	
29-56	4824-4832	patients	_	
29-57	4832-4833	.	_	

#Text=Methods
#Text=Participants
#Text=Sixty male former heroin addicts were recruited from the outpatient of the Baqiao Methadone Maintenance Treatment Center in Xi’an, Shaanxi Province, China.
30-1	4834-4841	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
30-2	4842-4854	Participants	_	
30-3	4855-4860	Sixty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-4	4861-4865	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-5	4866-4872	former	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-6	4873-4879	heroin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-7	4880-4887	addicts	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-8	4888-4892	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-9	4893-4902	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-10	4903-4907	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-11	4908-4911	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-12	4912-4922	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-13	4923-4925	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-14	4926-4929	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-15	4930-4936	Baqiao	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-16	4937-4946	Methadone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-17	4947-4958	Maintenance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-18	4959-4968	Treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-19	4969-4975	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-20	4976-4978	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-21	4979-4981	Xi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-22	4981-4982	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-23	4982-4984	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-24	4984-4985	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-25	4986-4993	Shaanxi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-26	4994-5002	Province	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-27	5002-5003	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-28	5004-5009	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-29	5009-5010	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Patients were eligible for enrollment if they (a) met the diagnostic criteria of DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) for heroin addiction; (b) willingly received long-term and stable MMT; (c) received at least three-month MMT; (d) were right-handed as judged by the Edinburgh Handedness Inventory.
31-1	5011-5019	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-2	5020-5024	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-3	5025-5033	eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-4	5034-5037	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-5	5038-5048	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-6	5049-5051	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-7	5052-5056	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-8	5057-5058	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-9	5058-5059	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-10	5059-5060	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-11	5061-5064	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-12	5065-5068	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-13	5069-5079	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-14	5080-5088	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-15	5089-5091	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-16	5092-5098	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-17	5099-5100	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-18	5100-5110	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-19	5111-5114	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-20	5115-5126	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-21	5127-5133	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-22	5134-5136	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-23	5137-5143	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-24	5144-5153	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-25	5153-5154	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-26	5155-5161	Fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-27	5162-5169	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-28	5169-5170	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-29	5171-5174	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-30	5175-5181	heroin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-31	5182-5191	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-32	5191-5192	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-33	5193-5194	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-34	5194-5195	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-35	5195-5196	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-36	5197-5206	willingly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-37	5207-5215	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-38	5216-5225	long-term	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-39	5226-5229	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-40	5230-5236	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-41	5237-5240	MMT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-42	5240-5241	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-43	5242-5243	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-44	5243-5244	c	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-45	5244-5245	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-46	5246-5254	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-47	5255-5257	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-48	5258-5263	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-49	5264-5275	three-month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-50	5276-5279	MMT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-51	5279-5280	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-52	5281-5282	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-53	5282-5283	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-54	5283-5284	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-55	5285-5289	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-56	5290-5302	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-57	5303-5305	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-58	5306-5312	judged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-59	5313-5315	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-60	5316-5319	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-61	5320-5329	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-62	5330-5340	Handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-63	5341-5350	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
31-64	5350-5351	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Patients were excluded if they (a) had a history of active neurological and psychiatric disorders besides heroin addiction, (b) had a history of head trauma, medical disorder requiring immediate treatment, and contraindications to MRI examination.
32-1	5352-5360	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-2	5361-5365	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-3	5366-5374	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-4	5375-5377	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-5	5378-5382	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-6	5383-5384	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-7	5384-5385	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-8	5385-5386	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-9	5387-5390	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-10	5391-5392	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-11	5393-5400	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-12	5401-5403	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-13	5404-5410	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-14	5411-5423	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-15	5424-5427	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-16	5428-5439	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-17	5440-5449	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-18	5450-5457	besides	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-19	5458-5464	heroin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-20	5465-5474	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-21	5474-5475	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-22	5476-5477	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-23	5477-5478	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-24	5478-5479	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-25	5480-5483	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-26	5484-5485	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-27	5486-5493	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-28	5494-5496	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-29	5497-5501	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-30	5502-5508	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-31	5508-5509	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-32	5510-5517	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-33	5518-5526	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-34	5527-5536	requiring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-35	5537-5546	immediate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-36	5547-5556	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-37	5556-5557	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-38	5558-5561	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-39	5562-5579	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-40	5580-5582	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-41	5583-5586	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-42	5587-5598	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-43	5598-5599	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Additionally, co-morbidity of addiction and psychiatric disorders is very common in heroin addicts, and to avoid the potential influence of psychiatric symptoms, we excluded the patients who reported having a current or past psychiatric illness other than heroin addiction, as described in exclusion criteria.
33-1	5600-5612	Additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-2	5612-5613	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-3	5614-5626	co-morbidity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-4	5627-5629	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-5	5630-5639	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-6	5640-5643	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-7	5644-5655	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-8	5656-5665	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-9	5666-5668	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-10	5669-5673	very	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-11	5674-5680	common	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-12	5681-5683	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-13	5684-5690	heroin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[20]	
33-14	5691-5698	addicts	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[20]	
33-15	5698-5699	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-16	5700-5703	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-17	5704-5706	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-18	5707-5712	avoid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-19	5713-5716	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-20	5717-5726	potential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-21	5727-5736	influence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-22	5737-5739	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-23	5740-5751	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-24	5752-5760	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-25	5760-5761	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-26	5762-5764	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-27	5765-5773	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-28	5774-5777	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-29	5778-5786	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-30	5787-5790	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-31	5791-5799	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-32	5800-5806	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-33	5807-5808	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-34	5809-5816	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-35	5817-5819	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-36	5820-5824	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-37	5825-5836	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-38	5837-5844	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-39	5845-5850	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-40	5851-5855	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-41	5856-5862	heroin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[21]	
33-42	5863-5872	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[21]	
33-43	5872-5873	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-44	5874-5876	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-45	5877-5886	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-46	5887-5889	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-47	5890-5899	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-48	5900-5908	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
33-49	5908-5909	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=We also evaluated the baseline psychological problems which usually accompanied with heroin addiction, such as depression and anxiety.
34-1	5910-5912	We	_	
34-2	5913-5917	also	_	
34-3	5918-5927	evaluated	_	
34-4	5928-5931	the	_	
34-5	5932-5940	baseline	_	
34-6	5941-5954	psychological	_	
34-7	5955-5963	problems	_	
34-8	5964-5969	which	_	
34-9	5970-5977	usually	_	
34-10	5978-5989	accompanied	_	
34-11	5990-5994	with	_	
34-12	5995-6001	heroin	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[22]	
34-13	6002-6011	addiction	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[22]	
34-14	6011-6012	,	_	
34-15	6013-6017	such	_	
34-16	6018-6020	as	_	
34-17	6021-6031	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression	
34-18	6032-6035	and	_	
34-19	6036-6043	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder	
34-20	6043-6044	.	_	

#Text=The Beck Depression Inventory II and Hamilton Anxiety Scale were used to evaluate the severity of depression and anxiety symptoms respectively.
35-1	6045-6048	The	_	
35-2	6049-6053	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[23]	
35-3	6054-6064	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[23]	
35-4	6065-6074	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[23]	
35-5	6075-6077	II	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[23]	
35-6	6078-6081	and	_	
35-7	6082-6090	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale[24]	
35-8	6091-6098	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale[24]	
35-9	6099-6104	Scale	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale[24]	
35-10	6105-6109	were	_	
35-11	6110-6114	used	_	
35-12	6115-6117	to	_	
35-13	6118-6126	evaluate	_	
35-14	6127-6130	the	_	
35-15	6131-6139	severity	http://maven.renci.org/NeuroBridge/neurobridge#Depression[25]	
35-16	6140-6142	of	http://maven.renci.org/NeuroBridge/neurobridge#Depression[25]	
35-17	6143-6153	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression[25]	
35-18	6154-6157	and	_	
35-19	6158-6165	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder	
35-20	6166-6174	symptoms	_	
35-21	6175-6187	respectively	_	
35-22	6187-6188	.	_	

#Text=There were no significant differences in depression severity and anxiety level between groups (data not shown).
36-1	6189-6194	There	_	
36-2	6195-6199	were	_	
36-3	6200-6202	no	_	
36-4	6203-6214	significant	_	
36-5	6215-6226	differences	_	
36-6	6227-6229	in	_	
36-7	6230-6240	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression[26]	
36-8	6241-6249	severity	http://maven.renci.org/NeuroBridge/neurobridge#Depression[26]	
36-9	6250-6253	and	_	
36-10	6254-6261	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder	
36-11	6262-6267	level	_	
36-12	6268-6275	between	_	
36-13	6276-6282	groups	_	
36-14	6283-6284	(	_	
36-15	6284-6288	data	_	
36-16	6289-6292	not	_	
36-17	6293-6298	shown	_	
36-18	6298-6299	)	_	
36-19	6299-6300	.	_	

#Text=This study was approved by Institutional Board of the Fourth Military Medical University, Xi’an, China and conducted in accordance with Declaration of Helsinki.
37-1	6301-6305	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-2	6306-6311	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-3	6312-6315	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-4	6316-6324	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-5	6325-6327	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-6	6328-6341	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-7	6342-6347	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-8	6348-6350	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-9	6351-6354	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-10	6355-6361	Fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-11	6362-6370	Military	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-12	6371-6378	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-13	6379-6389	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-14	6389-6390	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-15	6391-6393	Xi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-16	6393-6394	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-17	6394-6396	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-18	6396-6397	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-19	6398-6403	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-20	6404-6407	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-21	6408-6417	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-22	6418-6420	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-23	6421-6431	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-24	6432-6436	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-25	6437-6448	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-26	6449-6451	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-27	6452-6460	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
37-28	6460-6461	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=All participants were fully informed about the details of experiment and signed the written consents for their involvement and The proposed protocol conforms to the Good Clinical Practice and has been approved by the Ethics Committee of the Institute of Tangdu Hospital, Fourth Military Medical University, Shaanxi, China.
38-1	6462-6465	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-2	6466-6478	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-3	6479-6483	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-4	6484-6489	fully	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-5	6490-6498	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-6	6499-6504	about	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-7	6505-6508	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-8	6509-6516	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-9	6517-6519	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-10	6520-6530	experiment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-11	6531-6534	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-12	6535-6541	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-13	6542-6545	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-14	6546-6553	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-15	6554-6562	consents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-16	6563-6566	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-17	6567-6572	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-18	6573-6584	involvement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-19	6585-6588	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-20	6589-6592	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-21	6593-6601	proposed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-22	6602-6610	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-23	6611-6619	conforms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-24	6620-6622	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-25	6623-6626	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-26	6627-6631	Good	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-27	6632-6640	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-28	6641-6649	Practice	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-29	6650-6653	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-30	6654-6657	has	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-31	6658-6662	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-32	6663-6671	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-33	6672-6674	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-34	6675-6678	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-35	6679-6685	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-36	6686-6695	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-37	6696-6698	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-38	6699-6702	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-39	6703-6712	Institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-40	6713-6715	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-41	6716-6722	Tangdu	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-42	6723-6731	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-43	6731-6732	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-44	6733-6739	Fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-45	6740-6748	Military	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-46	6749-6756	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-47	6757-6767	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-48	6767-6768	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-49	6769-6776	Shaanxi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-50	6776-6777	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-51	6778-6783	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
38-52	6783-6784	.	_	

#Text=Experiment design and procedure
#Text=There were 60 participants recruited in the study.
39-1	6785-6795	Experiment	_	
39-2	6796-6802	design	_	
39-3	6803-6806	and	_	
39-4	6807-6816	procedure	_	
39-5	6817-6822	There	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-6	6823-6827	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-7	6828-6830	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-8	6831-6843	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-9	6844-6853	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-10	6854-6856	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-11	6857-6860	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-12	6861-6866	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
39-13	6866-6867	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	

#Text=According to the inclusion criteria exclusion criteria, 20 participants were excluded for having other active neurological and psychiatric disorders, head trauma, or contraindications to MRI examination, and 40 were included and then received a baseline resting-state fMRI scanning following with a succeeding 12-month clinical follow-up.
40-1	6868-6877	According	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-2	6878-6880	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-3	6881-6884	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-4	6885-6894	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-5	6895-6903	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-6	6904-6913	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-7	6914-6922	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-8	6922-6923	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-9	6924-6926	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-10	6927-6939	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-11	6940-6944	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-12	6945-6953	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-13	6954-6957	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-14	6958-6964	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-15	6965-6970	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-16	6971-6977	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-17	6978-6990	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-18	6991-6994	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-19	6995-7006	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-20	7007-7016	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-21	7016-7017	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-22	7018-7022	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-23	7023-7029	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-24	7029-7030	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-25	7031-7033	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-26	7034-7051	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-27	7052-7054	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-28	7055-7058	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-29	7059-7070	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-30	7070-7071	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-31	7072-7075	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-32	7076-7078	40	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-33	7079-7083	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-34	7084-7092	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-35	7093-7096	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-36	7097-7101	then	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-37	7102-7110	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-38	7111-7112	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-39	7113-7121	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-40	7122-7135	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[31]	
40-41	7136-7140	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[31]	
40-42	7141-7149	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-43	7150-7159	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-44	7160-7164	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-45	7165-7166	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-46	7167-7177	succeeding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-47	7178-7180	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-48	7180-7181	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-49	7181-7186	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-50	7187-7195	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-51	7196-7205	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
40-52	7205-7206	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	

#Text=During the follow-up, they were supervised under monthly structured interview and urine tests.
41-1	7207-7213	During	_	
41-2	7214-7217	the	_	
41-3	7218-7227	follow-up	_	
41-4	7227-7228	,	_	
41-5	7229-7233	they	_	
41-6	7234-7238	were	_	
41-7	7239-7249	supervised	_	
41-8	7250-7255	under	_	
41-9	7256-7263	monthly	_	
41-10	7264-7274	structured	_	
41-11	7275-7284	interview	_	
41-12	7285-7288	and	_	
41-13	7289-7294	urine	_	
41-14	7295-7300	tests	_	
41-15	7300-7301	.	_	

#Text=The participants with once self-reported heroin use or/and positive urine tests were defined as heroin relapser, and those with negative results in tests were defined as non-relapser.
42-1	7302-7305	The	_	
42-2	7306-7318	participants	_	
42-3	7319-7323	with	_	
42-4	7324-7328	once	_	
42-5	7329-7342	self-reported	_	
42-6	7343-7349	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[32]	
42-7	7350-7353	use	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[32]	
42-8	7354-7356	or	_	
42-9	7356-7357	/	_	
42-10	7357-7360	and	_	
42-11	7361-7369	positive	_	
42-12	7370-7375	urine	_	
42-13	7376-7381	tests	_	
42-14	7382-7386	were	_	
42-15	7387-7394	defined	_	
42-16	7395-7397	as	_	
42-17	7398-7404	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[33]	
42-18	7405-7413	relapser	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[33]	
42-19	7413-7414	,	_	
42-20	7415-7418	and	_	
42-21	7419-7424	those	_	
42-22	7425-7429	with	_	
42-23	7430-7438	negative	_	
42-24	7439-7446	results	_	
42-25	7447-7449	in	_	
42-26	7450-7455	tests	_	
42-27	7456-7460	were	_	
42-28	7461-7468	defined	_	
42-29	7469-7471	as	_	
42-30	7472-7484	non-relapser	_	
42-31	7484-7485	.	_	

#Text=Relapse rate of each heroin relapser was calculated as following: total numbers of positive results in tests during MMT/12.
43-1	7486-7493	Relapse	_	
43-2	7494-7498	rate	_	
43-3	7499-7501	of	_	
43-4	7502-7506	each	_	
43-5	7507-7513	heroin	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[34]	
43-6	7514-7522	relapser	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[34]	
43-7	7523-7526	was	_	
43-8	7527-7537	calculated	_	
43-9	7538-7540	as	_	
43-10	7541-7550	following	_	
43-11	7550-7551	:	_	
43-12	7552-7557	total	_	
43-13	7558-7565	numbers	_	
43-14	7566-7568	of	_	
43-15	7569-7577	positive	_	
43-16	7578-7585	results	_	
43-17	7586-7588	in	_	
43-18	7589-7594	tests	_	
43-19	7595-7601	during	_	
43-20	7602-7605	MMT	_	
43-21	7605-7606	/	_	
43-22	7606-7608	12	_	
43-23	7608-7609	.	_	

#Text=The subjective heroin craving was assessed by a 0–10 score visual analogue scale (VAS).
44-1	7610-7613	The	_	
44-2	7614-7624	subjective	_	
44-3	7625-7631	heroin	_	
44-4	7632-7639	craving	_	
44-5	7640-7643	was	_	
44-6	7644-7652	assessed	_	
44-7	7653-7655	by	_	
44-8	7656-7657	a	_	
44-9	7658-7659	0	_	
44-10	7659-7660	–	_	
44-11	7660-7662	10	_	
44-12	7663-7668	score	_	
44-13	7669-7675	visual	_	
44-14	7676-7684	analogue	_	
44-15	7685-7690	scale	_	
44-16	7691-7692	(	_	
44-17	7692-7695	VAS	_	
44-18	7695-7696	)	_	
44-19	7696-7697	.	_	

#Text=Image acquisition
#Text=All MRI scans were conducted on a Signa EXCITEHD 3.0 T scanner (GE Healthcare, Milwaukee, USA) with an eight-channel head coil.
45-1	7698-7703	Image	_	
45-2	7704-7715	acquisition	_	
45-3	7716-7719	All	_	
45-4	7720-7723	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
45-5	7724-7729	scans	_	
45-6	7730-7734	were	_	
45-7	7735-7744	conducted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-8	7745-7747	on	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-9	7748-7749	a	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-10	7750-7755	Signa	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-11	7756-7764	EXCITEHD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-12	7765-7768	3.0	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-13	7768-7769	 	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-14	7769-7770	T	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-15	7771-7778	scanner	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-16	7779-7780	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-17	7780-7782	GE	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-18	7783-7793	Healthcare	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-19	7793-7794	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-20	7795-7804	Milwaukee	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-21	7804-7805	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-22	7806-7809	USA	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-23	7809-7810	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-24	7811-7815	with	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-25	7816-7818	an	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-26	7819-7832	eight-channel	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-27	7833-7837	head	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-28	7838-7842	coil	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	
45-29	7842-7843	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[35]	

#Text=A routine T2WI structural scan (parameters: TR = 5100 ms, TE = 117 ms, matrix = 416 × 416, FOV = 24 × 24 cm2, slice thickness = 5.5 mm, gap = 0.8 mm) was performed to exclude gross cerebral pathology and then a BOLD functional imaging data was acquired using T2*-weighted gradient-echo planar imaging pulse sequence (GE-EPI, 32 axial slices covering the whole brain, 150 volumes).
46-1	7844-7845	A	_	
46-2	7846-7853	routine	_	
46-3	7854-7858	T2WI	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[36]	
46-4	7859-7869	structural	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[36]	
46-5	7870-7874	scan	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[36]	
46-6	7875-7876	(	_	
46-7	7876-7886	parameters	_	
46-8	7886-7887	:	_	
46-9	7888-7890	TR	_	
46-10	7891-7892	=	_	
46-11	7893-7897	5100	_	
46-12	7897-7898	 	_	
46-13	7898-7900	ms	_	
46-14	7900-7901	,	_	
46-15	7902-7904	TE	_	
46-16	7905-7906	=	_	
46-17	7907-7910	117	_	
46-18	7910-7911	 	_	
46-19	7911-7913	ms	_	
46-20	7913-7914	,	_	
46-21	7915-7921	matrix	_	
46-22	7922-7923	=	_	
46-23	7924-7927	416	_	
46-24	7928-7929	×	_	
46-25	7930-7933	416	_	
46-26	7933-7934	,	_	
46-27	7935-7938	FOV	_	
46-28	7939-7940	=	_	
46-29	7941-7943	24	_	
46-30	7944-7945	×	_	
46-31	7946-7948	24	_	
46-32	7948-7949	 	_	
46-33	7949-7952	cm2	_	
46-34	7952-7953	,	_	
46-35	7954-7959	slice	_	
46-36	7960-7969	thickness	_	
46-37	7970-7971	=	_	
46-38	7972-7975	5.5	_	
46-39	7975-7976	 	_	
46-40	7976-7978	mm	_	
46-41	7978-7979	,	_	
46-42	7980-7983	gap	_	
46-43	7984-7985	=	_	
46-44	7986-7989	0.8	_	
46-45	7989-7990	 	_	
46-46	7990-7992	mm	_	
46-47	7992-7993	)	_	
46-48	7994-7997	was	_	
46-49	7998-8007	performed	_	
46-50	8008-8010	to	_	
46-51	8011-8018	exclude	_	
46-52	8019-8024	gross	_	
46-53	8025-8033	cerebral	_	
46-54	8034-8043	pathology	_	
46-55	8044-8047	and	_	
46-56	8048-8052	then	_	
46-57	8053-8054	a	_	
46-58	8055-8059	BOLD	_	
46-59	8060-8070	functional	_	
46-60	8071-8078	imaging	_	
46-61	8079-8083	data	_	
46-62	8084-8087	was	_	
46-63	8088-8096	acquired	_	
46-64	8097-8102	using	_	
46-65	8103-8105	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
46-66	8105-8106	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
46-67	8106-8107	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
46-68	8107-8115	weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
46-69	8116-8129	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
46-70	8130-8136	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
46-71	8137-8144	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
46-72	8145-8150	pulse	_	
46-73	8151-8159	sequence	_	
46-74	8160-8161	(	_	
46-75	8161-8167	GE-EPI	_	
46-76	8167-8168	,	_	
46-77	8169-8171	32	_	
46-78	8172-8177	axial	_	
46-79	8178-8184	slices	_	
46-80	8185-8193	covering	_	
46-81	8194-8197	the	_	
46-82	8198-8203	whole	_	
46-83	8204-8209	brain	_	
46-84	8209-8210	,	_	
46-85	8211-8214	150	_	
46-86	8215-8222	volumes	_	
46-87	8222-8223	)	_	
46-88	8223-8224	.	_	

#Text=The parameters were set as follows: TR = 2000 ms, TE = 30 ms, flip angle = 90°, matrix = 64 × 64, FOV = 256 × 256 mm2, slice thickness = 4 mm, gap = 0 mm; spatial resolution = 4 × 4 × 4 mm3.
47-1	8225-8228	The	_	
47-2	8229-8239	parameters	_	
47-3	8240-8244	were	_	
47-4	8245-8248	set	_	
47-5	8249-8251	as	_	
47-6	8252-8259	follows	_	
47-7	8259-8260	:	_	
47-8	8261-8263	TR	_	
47-9	8264-8265	=	_	
47-10	8266-8270	2000	_	
47-11	8270-8271	 	_	
47-12	8271-8273	ms	_	
47-13	8273-8274	,	_	
47-14	8275-8277	TE	_	
47-15	8278-8279	=	_	
47-16	8280-8282	30	_	
47-17	8282-8283	 	_	
47-18	8283-8285	ms	_	
47-19	8285-8286	,	_	
47-20	8287-8291	flip	_	
47-21	8292-8297	angle	_	
47-22	8298-8299	=	_	
47-23	8300-8302	90	_	
47-24	8302-8303	°	_	
47-25	8303-8304	,	_	
47-26	8305-8311	matrix	_	
47-27	8312-8313	=	_	
47-28	8314-8316	64	_	
47-29	8317-8318	×	_	
47-30	8319-8321	64	_	
47-31	8321-8322	,	_	
47-32	8323-8326	FOV	_	
47-33	8327-8328	=	_	
47-34	8329-8332	256	_	
47-35	8333-8334	×	_	
47-36	8335-8338	256	_	
47-37	8338-8339	 	_	
47-38	8339-8342	mm2	_	
47-39	8342-8343	,	_	
47-40	8344-8349	slice	_	
47-41	8350-8359	thickness	_	
47-42	8360-8361	=	_	
47-43	8362-8363	4	_	
47-44	8363-8364	 	_	
47-45	8364-8366	mm	_	
47-46	8366-8367	,	_	
47-47	8368-8371	gap	_	
47-48	8372-8373	=	_	
47-49	8374-8375	0	_	
47-50	8375-8376	 	_	
47-51	8376-8378	mm	_	
47-52	8378-8379	;	_	
47-53	8380-8387	spatial	_	
47-54	8388-8398	resolution	_	
47-55	8399-8400	=	_	
47-56	8401-8402	4	_	
47-57	8403-8404	×	_	
47-58	8405-8406	4	_	
47-59	8407-8408	×	_	
47-60	8409-8410	4	_	
47-61	8410-8411	 	_	
47-62	8411-8414	mm3	_	
47-63	8414-8415	.	_	

#Text=The corresponding high-resolution fast spoiled gradient-echo 3D T1-weighted images were also collected for anatomical overlays of the functional data and for spatial normalization of the datasets to a standard atlas and settings were as following: TR = 7.8 ms, TE = 3.0 ms, matrix = 256 × 256, FOV = 256 × 256 mm2, spatial resolution =1 × 1 × 1 mm3.
48-1	8416-8419	The	_	
48-2	8420-8433	corresponding	_	
48-3	8434-8449	high-resolution	_	
48-4	8450-8454	fast	_	
48-5	8455-8462	spoiled	_	
48-6	8463-8476	gradient-echo	_	
48-7	8477-8479	3D	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
48-8	8480-8482	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
48-9	8482-8483	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
48-10	8483-8491	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
48-11	8492-8498	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
48-12	8499-8503	were	_	
48-13	8504-8508	also	_	
48-14	8509-8518	collected	_	
48-15	8519-8522	for	_	
48-16	8523-8533	anatomical	_	
48-17	8534-8542	overlays	_	
48-18	8543-8545	of	_	
48-19	8546-8549	the	_	
48-20	8550-8560	functional	_	
48-21	8561-8565	data	_	
48-22	8566-8569	and	_	
48-23	8570-8573	for	_	
48-24	8574-8581	spatial	_	
48-25	8582-8595	normalization	_	
48-26	8596-8598	of	_	
48-27	8599-8602	the	_	
48-28	8603-8611	datasets	_	
48-29	8612-8614	to	_	
48-30	8615-8616	a	_	
48-31	8617-8625	standard	_	
48-32	8626-8631	atlas	_	
48-33	8632-8635	and	_	
48-34	8636-8644	settings	_	
48-35	8645-8649	were	_	
48-36	8650-8652	as	_	
48-37	8653-8662	following	_	
48-38	8662-8663	:	_	
48-39	8664-8666	TR	_	
48-40	8667-8668	=	_	
48-41	8669-8672	7.8	_	
48-42	8672-8673	 	_	
48-43	8673-8675	ms	_	
48-44	8675-8676	,	_	
48-45	8677-8679	TE	_	
48-46	8680-8681	=	_	
48-47	8682-8685	3.0	_	
48-48	8685-8686	 	_	
48-49	8686-8688	ms	_	
48-50	8688-8689	,	_	
48-51	8690-8696	matrix	_	
48-52	8697-8698	=	_	
48-53	8699-8702	256	_	
48-54	8703-8704	×	_	
48-55	8705-8708	256	_	
48-56	8708-8709	,	_	
48-57	8710-8713	FOV	_	
48-58	8714-8715	=	_	
48-59	8716-8719	256	_	
48-60	8720-8721	×	_	
48-61	8722-8725	256	_	
48-62	8725-8726	 	_	
48-63	8726-8729	mm2	_	
48-64	8729-8730	,	_	
48-65	8731-8738	spatial	_	
48-66	8739-8749	resolution	_	
48-67	8750-8751	=	_	
48-68	8751-8752	1	_	
48-69	8753-8754	×	_	
48-70	8755-8756	1	_	
48-71	8757-8758	×	_	
48-72	8759-8760	1	_	
48-73	8760-8761	 	_	
48-74	8761-8764	mm3	_	
48-75	8764-8765	.	_	

#Text=Data processing and regional homogeneity calculation
#Text=Data preprocessing was performed with software (SPM12; http://www.fil.ion.ucl.ac.uk/spm) as described previously.
49-1	8766-8770	Data	_	
49-2	8771-8781	processing	_	
49-3	8782-8785	and	_	
49-4	8786-8794	regional	_	
49-5	8795-8806	homogeneity	_	
49-6	8807-8818	calculation	_	
49-7	8819-8823	Data	_	
49-8	8824-8837	preprocessing	_	
49-9	8838-8841	was	_	
49-10	8842-8851	performed	_	
49-11	8852-8856	with	_	
49-12	8857-8865	software	_	
49-13	8866-8867	(	_	
49-14	8867-8872	SPM12	_	
49-15	8872-8873	;	_	
49-16	8874-8878	http	_	
49-17	8878-8879	:	_	
49-18	8879-8880	/	_	
49-19	8880-8881	/	_	
49-20	8881-8902	www.fil.ion.ucl.ac.uk	_	
49-21	8902-8903	/	_	
49-22	8903-8906	spm	_	
49-23	8906-8907	)	_	
49-24	8908-8910	as	_	
49-25	8911-8920	described	_	
49-26	8921-8931	previously	_	
49-27	8931-8932	.	_	

#Text=In brief, for each participant the first 10 time points were discarded to avoid transient signal changes before magnetization reached steady state.
50-1	8933-8935	In	_	
50-2	8936-8941	brief	_	
50-3	8941-8942	,	_	
50-4	8943-8946	for	_	
50-5	8947-8951	each	_	
50-6	8952-8963	participant	_	
50-7	8964-8967	the	_	
50-8	8968-8973	first	_	
50-9	8974-8976	10	_	
50-10	8977-8981	time	_	
50-11	8982-8988	points	_	
50-12	8989-8993	were	_	
50-13	8994-9003	discarded	_	
50-14	9004-9006	to	_	
50-15	9007-9012	avoid	_	
50-16	9013-9022	transient	_	
50-17	9023-9029	signal	_	
50-18	9030-9037	changes	_	
50-19	9038-9044	before	_	
50-20	9045-9058	magnetization	_	
50-21	9059-9066	reached	_	
50-22	9067-9073	steady	_	
50-23	9074-9079	state	_	
50-24	9079-9080	.	_	

#Text=Translation and rotation were checked and subjects with head movements exceeding than 1 mm in any direction or head rotations greater than 1° were discarded.
51-1	9081-9092	Translation	_	
51-2	9093-9096	and	_	
51-3	9097-9105	rotation	_	
51-4	9106-9110	were	_	
51-5	9111-9118	checked	_	
51-6	9119-9122	and	_	
51-7	9123-9131	subjects	_	
51-8	9132-9136	with	_	
51-9	9137-9141	head	_	
51-10	9142-9151	movements	_	
51-11	9152-9161	exceeding	_	
51-12	9162-9166	than	_	
51-13	9167-9168	1	_	
51-14	9168-9169	 	_	
51-15	9169-9171	mm	_	
51-16	9172-9174	in	_	
51-17	9175-9178	any	_	
51-18	9179-9188	direction	_	
51-19	9189-9191	or	_	
51-20	9192-9196	head	_	
51-21	9197-9206	rotations	_	
51-22	9207-9214	greater	_	
51-23	9215-9219	than	_	
51-24	9220-9221	1	_	
51-25	9221-9222	°	_	
51-26	9223-9227	were	_	
51-27	9228-9237	discarded	_	
51-28	9237-9238	.	_	

#Text=After the motion correction, spatial normalization was made to the Montreal Neurological Institute (MNI) template (resampling voxel size = 3 × 3 × 3 mm3).
52-1	9239-9244	After	_	
52-2	9245-9248	the	_	
52-3	9249-9255	motion	_	
52-4	9256-9266	correction	_	
52-5	9266-9267	,	_	
52-6	9268-9275	spatial	_	
52-7	9276-9289	normalization	_	
52-8	9290-9293	was	_	
52-9	9294-9298	made	_	
52-10	9299-9301	to	_	
52-11	9302-9305	the	_	
52-12	9306-9314	Montreal	_	
52-13	9315-9327	Neurological	_	
52-14	9328-9337	Institute	_	
52-15	9338-9339	(	_	
52-16	9339-9342	MNI	_	
52-17	9342-9343	)	_	
52-18	9344-9352	template	_	
52-19	9353-9354	(	_	
52-20	9354-9364	resampling	_	
52-21	9365-9370	voxel	_	
52-22	9371-9375	size	_	
52-23	9376-9377	=	_	
52-24	9378-9379	3	_	
52-25	9380-9381	×	_	
52-26	9382-9383	3	_	
52-27	9384-9385	×	_	
52-28	9386-9387	3	_	
52-29	9387-9388	 	_	
52-30	9388-9391	mm3	_	
52-31	9391-9392	)	_	
52-32	9392-9393	.	_	

#Text=The T1-weighted high-resolution image volume was also spatially normalized to the MNI template.
53-1	9394-9397	The	_	
53-2	9398-9400	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
53-3	9400-9401	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
53-4	9401-9409	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
53-5	9410-9425	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
53-6	9426-9431	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
53-7	9432-9438	volume	_	
53-8	9439-9442	was	_	
53-9	9443-9447	also	_	
53-10	9448-9457	spatially	_	
53-11	9458-9468	normalized	_	
53-12	9469-9471	to	_	
53-13	9472-9475	the	_	
53-14	9476-9479	MNI	_	
53-15	9480-9488	template	_	
53-16	9488-9489	.	_	

#Text=All images spatially normalized to MNI template were transformed to Talairach and Tournoux coordinates and then filtered by using a band-passed filter (0.01–0.08 Hz) to reduce the effect of low-frequency drifts and high-frequency noise.
54-1	9490-9493	All	_	
54-2	9494-9500	images	_	
54-3	9501-9510	spatially	_	
54-4	9511-9521	normalized	_	
54-5	9522-9524	to	_	
54-6	9525-9528	MNI	_	
54-7	9529-9537	template	_	
54-8	9538-9542	were	_	
54-9	9543-9554	transformed	_	
54-10	9555-9557	to	_	
54-11	9558-9567	Talairach	_	
54-12	9568-9571	and	_	
54-13	9572-9580	Tournoux	_	
54-14	9581-9592	coordinates	_	
54-15	9593-9596	and	_	
54-16	9597-9601	then	_	
54-17	9602-9610	filtered	_	
54-18	9611-9613	by	_	
54-19	9614-9619	using	_	
54-20	9620-9621	a	_	
54-21	9622-9633	band-passed	_	
54-22	9634-9640	filter	_	
54-23	9641-9642	(	_	
54-24	9642-9646	0.01	_	
54-25	9646-9647	–	_	
54-26	9647-9651	0.08	_	
54-27	9651-9652	 	_	
54-28	9652-9654	Hz	_	
54-29	9654-9655	)	_	
54-30	9656-9658	to	_	
54-31	9659-9665	reduce	_	
54-32	9666-9669	the	_	
54-33	9670-9676	effect	_	
54-34	9677-9679	of	_	
54-35	9680-9693	low-frequency	_	
54-36	9694-9700	drifts	_	
54-37	9701-9704	and	_	
54-38	9705-9719	high-frequency	_	
54-39	9720-9725	noise	_	
54-40	9725-9726	.	_	

#Text=All the data was collected and analyzed by an author (Y.B.L., 5 years of experience in fMRI analysis) who was blinded to the present study.
55-1	9727-9730	All	_	
55-2	9731-9734	the	_	
55-3	9735-9739	data	_	
55-4	9740-9743	was	_	
55-5	9744-9753	collected	_	
55-6	9754-9757	and	_	
55-7	9758-9766	analyzed	_	
55-8	9767-9769	by	_	
55-9	9770-9772	an	_	
55-10	9773-9779	author	_	
55-11	9780-9781	(	_	
55-12	9781-9786	Y.B.L	_	
55-13	9786-9787	.	_	
55-14	9787-9788	,	_	
55-15	9789-9790	5	_	
55-16	9790-9791	 	_	
55-17	9791-9796	years	_	
55-18	9797-9799	of	_	
55-19	9800-9810	experience	_	
55-20	9811-9813	in	_	
55-21	9814-9818	fMRI	_	
55-22	9819-9827	analysis	_	
55-23	9827-9828	)	_	
55-24	9829-9832	who	_	
55-25	9833-9836	was	_	
55-26	9837-9844	blinded	_	
55-27	9845-9847	to	_	
55-28	9848-9851	the	_	
55-29	9852-9859	present	_	
55-30	9860-9865	study	_	
55-31	9865-9866	.	_	

#Text=For regional homogeneity (ReHo) analysis, the data were processed with a software (REST1.8; http://resting-fmri.sourceforge.net).
56-1	9867-9870	For	_	
56-2	9871-9879	regional	_	
56-3	9880-9891	homogeneity	_	
56-4	9892-9893	(	_	
56-5	9893-9897	ReHo	_	
56-6	9897-9898	)	_	
56-7	9899-9907	analysis	_	
56-8	9907-9908	,	_	
56-9	9909-9912	the	_	
56-10	9913-9917	data	_	
56-11	9918-9922	were	_	
56-12	9923-9932	processed	_	
56-13	9933-9937	with	_	
56-14	9938-9939	a	_	
56-15	9940-9948	software	_	
56-16	9949-9950	(	_	
56-17	9950-9957	REST1.8	_	
56-18	9957-9958	;	_	
56-19	9959-9963	http	_	
56-20	9963-9964	:	_	
56-21	9964-9965	/	_	
56-22	9965-9966	/	_	
56-23	9966-9994	resting-fmri.sourceforge.net	_	
56-24	9994-9995	)	_	
56-25	9995-9996	.	_	

#Text=The ReHo calculation procedure was performed as previously reported.
57-1	9997-10000	The	_	
57-2	10001-10005	ReHo	_	
57-3	10006-10017	calculation	_	
57-4	10018-10027	procedure	_	
57-5	10028-10031	was	_	
57-6	10032-10041	performed	_	
57-7	10042-10044	as	_	
57-8	10045-10055	previously	_	
57-9	10056-10064	reported	_	
57-10	10064-10065	.	_	

#Text=In brief, it was performed on a voxel-by-voxel basis by calculating the Kendall Coefficient of Concordance (KCC) of the time series of a given voxel and that of its nearest neighbors.
58-1	10066-10068	In	_	
58-2	10069-10074	brief	_	
58-3	10074-10075	,	_	
58-4	10076-10078	it	_	
58-5	10079-10082	was	_	
58-6	10083-10092	performed	_	
58-7	10093-10095	on	_	
58-8	10096-10097	a	_	
58-9	10098-10112	voxel-by-voxel	_	
58-10	10113-10118	basis	_	
58-11	10119-10121	by	_	
58-12	10122-10133	calculating	_	
58-13	10134-10137	the	_	
58-14	10138-10145	Kendall	_	
58-15	10146-10157	Coefficient	_	
58-16	10158-10160	of	_	
58-17	10161-10172	Concordance	_	
58-18	10173-10174	(	_	
58-19	10174-10177	KCC	_	
58-20	10177-10178	)	_	
58-21	10179-10181	of	_	
58-22	10182-10185	the	_	
58-23	10186-10190	time	_	
58-24	10191-10197	series	_	
58-25	10198-10200	of	_	
58-26	10201-10202	a	_	
58-27	10203-10208	given	_	
58-28	10209-10214	voxel	_	
58-29	10215-10218	and	_	
58-30	10219-10223	that	_	
58-31	10224-10226	of	_	
58-32	10227-10230	its	_	
58-33	10231-10238	nearest	_	
58-34	10239-10248	neighbors	_	
58-35	10248-10249	.	_	

#Text=To reduce the influence of individual variation in the KCC, ReHo maps were normalized to the KCC of each voxel by the averaged KCC of the whole brain.
59-1	10250-10252	To	_	
59-2	10253-10259	reduce	_	
59-3	10260-10263	the	_	
59-4	10264-10273	influence	_	
59-5	10274-10276	of	_	
59-6	10277-10287	individual	_	
59-7	10288-10297	variation	_	
59-8	10298-10300	in	_	
59-9	10301-10304	the	_	
59-10	10305-10308	KCC	_	
59-11	10308-10309	,	_	
59-12	10310-10314	ReHo	_	
59-13	10315-10319	maps	_	
59-14	10320-10324	were	_	
59-15	10325-10335	normalized	_	
59-16	10336-10338	to	_	
59-17	10339-10342	the	_	
59-18	10343-10346	KCC	_	
59-19	10347-10349	of	_	
59-20	10350-10354	each	_	
59-21	10355-10360	voxel	_	
59-22	10361-10363	by	_	
59-23	10364-10367	the	_	
59-24	10368-10376	averaged	_	
59-25	10377-10380	KCC	_	
59-26	10381-10383	of	_	
59-27	10384-10387	the	_	
59-28	10388-10393	whole	_	
59-29	10394-10399	brain	_	
59-30	10399-10400	.	_	

#Text=The resulting data were then smoothed spatially with a 6-mm full width at half maximum Gaussian kernel to reduce noise and residual differences in gyral anatomy.
60-1	10401-10404	The	_	
60-2	10405-10414	resulting	_	
60-3	10415-10419	data	_	
60-4	10420-10424	were	_	
60-5	10425-10429	then	_	
60-6	10430-10438	smoothed	_	
60-7	10439-10448	spatially	_	
60-8	10449-10453	with	_	
60-9	10454-10455	a	_	
60-10	10456-10457	6	_	
60-11	10457-10458	-	_	
60-12	10458-10460	mm	_	
60-13	10461-10465	full	_	
60-14	10466-10471	width	_	
60-15	10472-10474	at	_	
60-16	10475-10479	half	_	
60-17	10480-10487	maximum	_	
60-18	10488-10496	Gaussian	_	
60-19	10497-10503	kernel	_	
60-20	10504-10506	to	_	
60-21	10507-10513	reduce	_	
60-22	10514-10519	noise	_	
60-23	10520-10523	and	_	
60-24	10524-10532	residual	_	
60-25	10533-10544	differences	_	
60-26	10545-10547	in	_	
60-27	10548-10553	gyral	_	
60-28	10554-10561	anatomy	_	
60-29	10561-10562	.	_	

#Text=Statistical analysis
#Text=To analyse the differences of ReHo values between heroin relapse and non-relapse patients under MMT, a two-sample t test was performed on the individual normalized ReHo maps in a voxel-by-voxel manner.
61-1	10563-10574	Statistical	_	
61-2	10575-10583	analysis	_	
61-3	10584-10586	To	_	
61-4	10587-10594	analyse	_	
61-5	10595-10598	the	_	
61-6	10599-10610	differences	_	
61-7	10611-10613	of	_	
61-8	10614-10618	ReHo	_	
61-9	10619-10625	values	_	
61-10	10626-10633	between	_	
61-11	10634-10640	heroin	_	
61-12	10641-10648	relapse	_	
61-13	10649-10652	and	_	
61-14	10653-10664	non-relapse	_	
61-15	10665-10673	patients	_	
61-16	10674-10679	under	_	
61-17	10680-10683	MMT	_	
61-18	10683-10684	,	_	
61-19	10685-10686	a	_	
61-20	10687-10697	two-sample	_	
61-21	10698-10699	t	_	
61-22	10700-10704	test	_	
61-23	10705-10708	was	_	
61-24	10709-10718	performed	_	
61-25	10719-10721	on	_	
61-26	10722-10725	the	_	
61-27	10726-10736	individual	_	
61-28	10737-10747	normalized	_	
61-29	10748-10752	ReHo	_	
61-30	10753-10757	maps	_	
61-31	10758-10760	in	_	
61-32	10761-10762	a	_	
61-33	10763-10777	voxel-by-voxel	_	
61-34	10778-10784	manner	_	
61-35	10784-10785	.	_	

#Text=A probability of p < 0.05 (corrected by FDR) was considered statistically significant.
62-1	10786-10787	A	_	
62-2	10788-10799	probability	_	
62-3	10800-10802	of	_	
62-4	10803-10804	p	_	
62-5	10805-10806	<	_	
62-6	10807-10811	0.05	_	
62-7	10812-10813	(	_	
62-8	10813-10822	corrected	_	
62-9	10823-10825	by	_	
62-10	10826-10829	FDR	_	
62-11	10829-10830	)	_	
62-12	10831-10834	was	_	
62-13	10835-10845	considered	_	
62-14	10846-10859	statistically	_	
62-15	10860-10871	significant	_	
62-16	10871-10872	.	_	

#Text=Correlation analysis
#Text=To evaluate the association of altered ReHo in different brain regions with heroin relapse in these relapsers, we performed Spearman's correlation analysis between mean ReHo values and relapse rates (as defined above) or subjective heroin craving indicated by VAS scores of each heroin relapser.
63-1	10873-10884	Correlation	_	
63-2	10885-10893	analysis	_	
63-3	10894-10896	To	_	
63-4	10897-10905	evaluate	_	
63-5	10906-10909	the	_	
63-6	10910-10921	association	_	
63-7	10922-10924	of	_	
63-8	10925-10932	altered	_	
63-9	10933-10937	ReHo	_	
63-10	10938-10940	in	_	
63-11	10941-10950	different	_	
63-12	10951-10956	brain	_	
63-13	10957-10964	regions	_	
63-14	10965-10969	with	_	
63-15	10970-10976	heroin	_	
63-16	10977-10984	relapse	_	
63-17	10985-10987	in	_	
63-18	10988-10993	these	_	
63-19	10994-11003	relapsers	_	
63-20	11003-11004	,	_	
63-21	11005-11007	we	_	
63-22	11008-11017	performed	_	
63-23	11018-11028	Spearman's	_	
63-24	11029-11040	correlation	_	
63-25	11041-11049	analysis	_	
63-26	11050-11057	between	_	
63-27	11058-11062	mean	_	
63-28	11063-11067	ReHo	_	
63-29	11068-11074	values	_	
63-30	11075-11078	and	_	
63-31	11079-11086	relapse	_	
63-32	11087-11092	rates	_	
63-33	11093-11094	(	_	
63-34	11094-11096	as	_	
63-35	11097-11104	defined	_	
63-36	11105-11110	above	_	
63-37	11110-11111	)	_	
63-38	11112-11114	or	_	
63-39	11115-11125	subjective	_	
63-40	11126-11132	heroin	_	
63-41	11133-11140	craving	_	
63-42	11141-11150	indicated	_	
63-43	11151-11153	by	_	
63-44	11154-11157	VAS	_	
63-45	11158-11164	scores	_	
63-46	11165-11167	of	_	
63-47	11168-11172	each	_	
63-48	11173-11179	heroin	_	
63-49	11180-11188	relapser	_	
63-50	11188-11189	.	_	

#Text=The correlation analysis was based on non-parametric Spearman correlations and included only the relapsers.
64-1	11190-11193	The	_	
64-2	11194-11205	correlation	_	
64-3	11206-11214	analysis	_	
64-4	11215-11218	was	_	
64-5	11219-11224	based	_	
64-6	11225-11227	on	_	
64-7	11228-11242	non-parametric	_	
64-8	11243-11251	Spearman	_	
64-9	11252-11264	correlations	_	
64-10	11265-11268	and	_	
64-11	11269-11277	included	_	
64-12	11278-11282	only	_	
64-13	11283-11286	the	_	
64-14	11287-11296	relapsers	_	
64-15	11296-11297	.	_	

#Text=Threshold levels of significance for correlation coefficients were adjusted for multiple comparisons by a Bonferroni’s correction (p value was set as 0.05, and the number of tests was 8).
65-1	11298-11307	Threshold	_	
65-2	11308-11314	levels	_	
65-3	11315-11317	of	_	
65-4	11318-11330	significance	_	
65-5	11331-11334	for	_	
65-6	11335-11346	correlation	_	
65-7	11347-11359	coefficients	_	
65-8	11360-11364	were	_	
65-9	11365-11373	adjusted	_	
65-10	11374-11377	for	_	
65-11	11378-11386	multiple	_	
65-12	11387-11398	comparisons	_	
65-13	11399-11401	by	_	
65-14	11402-11403	a	_	
65-15	11404-11414	Bonferroni	_	
65-16	11414-11415	’	_	
65-17	11415-11416	s	_	
65-18	11417-11427	correction	_	
65-19	11428-11429	(	_	
65-20	11429-11430	p	_	
65-21	11431-11436	value	_	
65-22	11437-11440	was	_	
65-23	11441-11444	set	_	
65-24	11445-11447	as	_	
65-25	11448-11452	0.05	_	
65-26	11452-11453	,	_	
65-27	11454-11457	and	_	
65-28	11458-11461	the	_	
65-29	11462-11468	number	_	
65-30	11469-11471	of	_	
65-31	11472-11477	tests	_	
65-32	11478-11481	was	_	
65-33	11482-11483	8	_	
65-34	11483-11484	)	_	
65-35	11484-11485	.	_	

#Text=Results
#Text=Clinical characteristics of participants (mean ± S.D.)
66-1	11486-11493	Results	_	
66-2	11494-11502	Clinical	_	
66-3	11503-11518	characteristics	_	
66-4	11519-11521	of	_	
66-5	11522-11534	participants	_	
66-6	11535-11536	(	_	
66-7	11536-11540	mean	_	
66-8	11541-11542	±	_	
66-9	11543-11546	S.D	_	
66-10	11546-11547	.	_	
66-11	11547-11548	)	_	

#Text=Characteristics\tNon-relapse (N =19)\tRelapse (N = 21)\tT-value\tp-value\t \tAge (years)\t39.3 ± 7.1\t35.6 ± 5.4\t1.74\t0.09\t \tEducation level (years)\t9.1 ± 2.6\t9.5 ± 2.2\t−0.49\t0.62\t \tCigarettes (per day)\t21 ± 8.5\t21.3 ± 10.1\t−0.12\t0.90\t \tDuration of cigarette smoking (months)\t275.7 ± 69.1\t224 ± 64.5\t2.29\t0.30\t \tDaily dosage of heroin abuse (g)\t0.3 ± 0.2\t0.3 ± 0.1\t0.16\t0.87\t \tAccumulated dosage of heroin abuse (g)\t1036.8 ± 1232.2\t918.8 ± 1186.9\t0.28\t0.77\t \tDuration of heroin abuse (months)\t275.7 ± 69.1\t224 ± 64.5\t0.49\t0.62\t \tAccumulated dosage of methadone use (l)\t41.6 ± 34.9\t30.6 ± 17.4\t1.16\t0.25\t \tDaily dosage of methadone use (ml)\t44.1 ± 19.5\t43.5 ± 11.8\t0.11\t0.91\t \t
#Text=
#Text=Note: Unless otherwise indicated, data are means ± standard deviations (S.D.)
67-1	11549-11564	Characteristics	_	
67-2	11565-11576	Non-relapse	_	
67-3	11577-11578	(	_	
67-4	11578-11579	N	_	
67-5	11580-11581	=	_	
67-6	11581-11583	19	_	
67-7	11583-11584	)	_	
67-8	11585-11592	Relapse	_	
67-9	11593-11594	(	_	
67-10	11594-11595	N	_	
67-11	11596-11597	=	_	
67-12	11598-11600	21	_	
67-13	11600-11601	)	_	
67-14	11602-11609	T-value	_	
67-15	11610-11617	p-value	_	
67-16	11620-11623	Age	_	
67-17	11624-11625	(	_	
67-18	11625-11630	years	_	
67-19	11630-11631	)	_	
67-20	11632-11636	39.3	_	
67-21	11637-11638	±	_	
67-22	11639-11642	7.1	_	
67-23	11643-11647	35.6	_	
67-24	11648-11649	±	_	
67-25	11650-11653	5.4	_	
67-26	11654-11658	1.74	_	
67-27	11659-11663	0.09	_	
67-28	11666-11675	Education	_	
67-29	11676-11681	level	_	
67-30	11682-11683	(	_	
67-31	11683-11688	years	_	
67-32	11688-11689	)	_	
67-33	11690-11693	9.1	_	
67-34	11694-11695	±	_	
67-35	11696-11699	2.6	_	
67-36	11700-11703	9.5	_	
67-37	11704-11705	±	_	
67-38	11706-11709	2.2	_	
67-39	11710-11711	−	_	
67-40	11711-11715	0.49	_	
67-41	11716-11720	0.62	_	
67-42	11723-11733	Cigarettes	_	
67-43	11734-11735	(	_	
67-44	11735-11738	per	_	
67-45	11739-11742	day	_	
67-46	11742-11743	)	_	
67-47	11744-11746	21	_	
67-48	11747-11748	±	_	
67-49	11749-11752	8.5	_	
67-50	11753-11757	21.3	_	
67-51	11758-11759	±	_	
67-52	11760-11764	10.1	_	
67-53	11765-11766	−	_	
67-54	11766-11770	0.12	_	
67-55	11771-11775	0.90	_	
67-56	11778-11786	Duration	_	
67-57	11787-11789	of	_	
67-58	11790-11799	cigarette	_	
67-59	11800-11807	smoking	_	
67-60	11808-11809	(	_	
67-61	11809-11815	months	_	
67-62	11815-11816	)	_	
67-63	11817-11822	275.7	_	
67-64	11823-11824	±	_	
67-65	11825-11829	69.1	_	
67-66	11830-11833	224	_	
67-67	11834-11835	±	_	
67-68	11836-11840	64.5	_	
67-69	11841-11845	2.29	_	
67-70	11846-11850	0.30	_	
67-71	11853-11858	Daily	_	
67-72	11859-11865	dosage	_	
67-73	11866-11868	of	_	
67-74	11869-11875	heroin	_	
67-75	11876-11881	abuse	_	
67-76	11882-11883	(	_	
67-77	11883-11884	g	_	
67-78	11884-11885	)	_	
67-79	11886-11889	0.3	_	
67-80	11890-11891	±	_	
67-81	11892-11895	0.2	_	
67-82	11896-11899	0.3	_	
67-83	11900-11901	±	_	
67-84	11902-11905	0.1	_	
67-85	11906-11910	0.16	_	
67-86	11911-11915	0.87	_	
67-87	11918-11929	Accumulated	_	
67-88	11930-11936	dosage	_	
67-89	11937-11939	of	_	
67-90	11940-11946	heroin	_	
67-91	11947-11952	abuse	_	
67-92	11953-11954	(	_	
67-93	11954-11955	g	_	
67-94	11955-11956	)	_	
67-95	11957-11963	1036.8	_	
67-96	11964-11965	±	_	
67-97	11966-11972	1232.2	_	
67-98	11973-11978	918.8	_	
67-99	11979-11980	±	_	
67-100	11981-11987	1186.9	_	
67-101	11988-11992	0.28	_	
67-102	11993-11997	0.77	_	
67-103	12000-12008	Duration	_	
67-104	12009-12011	of	_	
67-105	12012-12018	heroin	_	
67-106	12019-12024	abuse	_	
67-107	12025-12026	(	_	
67-108	12026-12032	months	_	
67-109	12032-12033	)	_	
67-110	12034-12039	275.7	_	
67-111	12040-12041	±	_	
67-112	12042-12046	69.1	_	
67-113	12047-12050	224	_	
67-114	12051-12052	±	_	
67-115	12053-12057	64.5	_	
67-116	12058-12062	0.49	_	
67-117	12063-12067	0.62	_	
67-118	12070-12081	Accumulated	_	
67-119	12082-12088	dosage	_	
67-120	12089-12091	of	_	
67-121	12092-12101	methadone	_	
67-122	12102-12105	use	_	
67-123	12106-12107	(	_	
67-124	12107-12108	l	_	
67-125	12108-12109	)	_	
67-126	12110-12114	41.6	_	
67-127	12115-12116	±	_	
67-128	12117-12121	34.9	_	
67-129	12122-12126	30.6	_	
67-130	12127-12128	±	_	
67-131	12129-12133	17.4	_	
67-132	12134-12138	1.16	_	
67-133	12139-12143	0.25	_	
67-134	12146-12151	Daily	_	
67-135	12152-12158	dosage	_	
67-136	12159-12161	of	_	
67-137	12162-12171	methadone	_	
67-138	12172-12175	use	_	
67-139	12176-12177	(	_	
67-140	12177-12179	ml	_	
67-141	12179-12180	)	_	
67-142	12181-12185	44.1	_	
67-143	12186-12187	±	_	
67-144	12188-12192	19.5	_	
67-145	12193-12197	43.5	_	
67-146	12198-12199	±	_	
67-147	12200-12204	11.8	_	
67-148	12205-12209	0.11	_	
67-149	12210-12214	0.91	_	
67-150	12219-12223	Note	_	
67-151	12223-12224	:	_	
67-152	12225-12231	Unless	_	
67-153	12232-12241	otherwise	_	
67-154	12242-12251	indicated	_	
67-155	12251-12252	,	_	
67-156	12253-12257	data	_	
67-157	12258-12261	are	_	
67-158	12262-12267	means	_	
67-159	12268-12269	±	_	
67-160	12270-12278	standard	_	
67-161	12279-12289	deviations	_	
67-162	12290-12291	(	_	
67-163	12291-12294	S.D	_	
67-164	12294-12295	.	_	
67-165	12295-12296	)	_	

#Text=Sixty male former heroin addicts were recruited in the present study.
68-1	12297-12302	Sixty	_	
68-2	12303-12307	male	_	
68-3	12308-12314	former	_	
68-4	12315-12321	heroin	_	
68-5	12322-12329	addicts	_	
68-6	12330-12334	were	_	
68-7	12335-12344	recruited	_	
68-8	12345-12347	in	_	
68-9	12348-12351	the	_	
68-10	12352-12359	present	_	
68-11	12360-12365	study	_	
68-12	12365-12366	.	_	

#Text=Due to head motion, abnormal brain structure and incomplete outcome data, forty were finally included according to the inclusion and exclusion criteria.
69-1	12367-12370	Due	_	
69-2	12371-12373	to	_	
69-3	12374-12378	head	_	
69-4	12379-12385	motion	_	
69-5	12385-12386	,	_	
69-6	12387-12395	abnormal	_	
69-7	12396-12401	brain	_	
69-8	12402-12411	structure	_	
69-9	12412-12415	and	_	
69-10	12416-12426	incomplete	_	
69-11	12427-12434	outcome	_	
69-12	12435-12439	data	_	
69-13	12439-12440	,	_	
69-14	12441-12446	forty	_	
69-15	12447-12451	were	_	
69-16	12452-12459	finally	_	
69-17	12460-12468	included	_	
69-18	12469-12478	according	_	
69-19	12479-12481	to	_	
69-20	12482-12485	the	_	
69-21	12486-12495	inclusion	_	
69-22	12496-12499	and	_	
69-23	12500-12509	exclusion	_	
69-24	12510-12518	criteria	_	
69-25	12518-12519	.	_	

#Text=After 12-month follow-up, 21 participants were classified as relapsers according to the defined criteria for relapse, and 19 as non-relapsers.
70-1	12520-12525	After	_	
70-2	12526-12528	12	_	
70-3	12528-12529	-	_	
70-4	12529-12534	month	_	
70-5	12535-12544	follow-up	_	
70-6	12544-12545	,	_	
70-7	12546-12548	21	_	
70-8	12549-12561	participants	_	
70-9	12562-12566	were	_	
70-10	12567-12577	classified	_	
70-11	12578-12580	as	_	
70-12	12581-12590	relapsers	_	
70-13	12591-12600	according	_	
70-14	12601-12603	to	_	
70-15	12604-12607	the	_	
70-16	12608-12615	defined	_	
70-17	12616-12624	criteria	_	
70-18	12625-12628	for	_	
70-19	12629-12636	relapse	_	
70-20	12636-12637	,	_	
70-21	12638-12641	and	_	
70-22	12642-12644	19	_	
70-23	12645-12647	as	_	
70-24	12648-12661	non-relapsers	_	
70-25	12661-12662	.	_	

#Text=There were no significant differences between heroin relapsers and non-relapsers in their age, education, number of cigarettes smoked per day, duration of cigarette smoking, duration of heroin abuse and daily/accumulated dosage of heroin/methadone (Table 1).
71-1	12663-12668	There	_	
71-2	12669-12673	were	_	
71-3	12674-12676	no	_	
71-4	12677-12688	significant	_	
71-5	12689-12700	differences	_	
71-6	12701-12708	between	_	
71-7	12709-12715	heroin	_	
71-8	12716-12725	relapsers	_	
71-9	12726-12729	and	_	
71-10	12730-12743	non-relapsers	_	
71-11	12744-12746	in	_	
71-12	12747-12752	their	_	
71-13	12753-12756	age	_	
71-14	12756-12757	,	_	
71-15	12758-12767	education	_	
71-16	12767-12768	,	_	
71-17	12769-12775	number	_	
71-18	12776-12778	of	_	
71-19	12779-12789	cigarettes	_	
71-20	12790-12796	smoked	_	
71-21	12797-12800	per	_	
71-22	12801-12804	day	_	
71-23	12804-12805	,	_	
71-24	12806-12814	duration	_	
71-25	12815-12817	of	_	
71-26	12818-12827	cigarette	_	
71-27	12828-12835	smoking	_	
71-28	12835-12836	,	_	
71-29	12837-12845	duration	_	
71-30	12846-12848	of	_	
71-31	12849-12855	heroin	_	
71-32	12856-12861	abuse	_	
71-33	12862-12865	and	_	
71-34	12866-12871	daily	_	
71-35	12871-12872	/	_	
71-36	12872-12883	accumulated	_	
71-37	12884-12890	dosage	_	
71-38	12891-12893	of	_	
71-39	12894-12900	heroin	_	
71-40	12900-12901	/	_	
71-41	12901-12910	methadone	_	
71-42	12911-12912	(	_	
71-43	12912-12917	Table	_	
71-44	12917-12918	 	_	
71-45	12918-12919	1	_	
71-46	12919-12920	)	_	
71-47	12920-12921	.	_	

#Text=Data show brain areas with abnormal ReHo in heroin relapsers compared with non-relapsers under MMT.
72-1	12922-12926	Data	_	
72-2	12927-12931	show	_	
72-3	12932-12937	brain	_	
72-4	12938-12943	areas	_	
72-5	12944-12948	with	_	
72-6	12949-12957	abnormal	_	
72-7	12958-12962	ReHo	_	
72-8	12963-12965	in	_	
72-9	12966-12972	heroin	_	
72-10	12973-12982	relapsers	_	
72-11	12983-12991	compared	_	
72-12	12992-12996	with	_	
72-13	12997-13010	non-relapsers	_	
72-14	13011-13016	under	_	
72-15	13017-13020	MMT	_	
72-16	13020-13021	.	_	

#Text=The differences are shown on whole-brain MR rendering (a) and MR axial view (every 3 mm, b).
73-1	13022-13025	The	_	
73-2	13026-13037	differences	_	
73-3	13038-13041	are	_	
73-4	13042-13047	shown	_	
73-5	13048-13050	on	_	
73-6	13051-13062	whole-brain	_	
73-7	13063-13065	MR	_	
73-8	13066-13075	rendering	_	
73-9	13076-13077	(	_	
73-10	13077-13078	a	_	
73-11	13078-13079	)	_	
73-12	13080-13083	and	_	
73-13	13084-13086	MR	_	
73-14	13087-13092	axial	_	
73-15	13093-13097	view	_	
73-16	13098-13099	(	_	
73-17	13099-13104	every	_	
73-18	13105-13106	3	_	
73-19	13106-13107	 	_	
73-20	13107-13109	mm	_	
73-21	13109-13110	,	_	
73-22	13111-13112	b	_	
73-23	13112-13113	)	_	
73-24	13113-13114	.	_	

#Text=Relapsers displayed increased ReHo in the bilateral medial OFC, right caudate, and right cerebellum (red) but decreased ReHo in the left parahippocampal gyrus, left middle temporal gyrus, right lingual gyrus, and precuneus (blue).
74-1	13115-13124	Relapsers	_	
74-2	13125-13134	displayed	_	
74-3	13135-13144	increased	_	
74-4	13145-13149	ReHo	_	
74-5	13150-13152	in	_	
74-6	13153-13156	the	_	
74-7	13157-13166	bilateral	_	
74-8	13167-13173	medial	_	
74-9	13174-13177	OFC	_	
74-10	13177-13178	,	_	
74-11	13179-13184	right	_	
74-12	13185-13192	caudate	_	
74-13	13192-13193	,	_	
74-14	13194-13197	and	_	
74-15	13198-13203	right	_	
74-16	13204-13214	cerebellum	_	
74-17	13215-13216	(	_	
74-18	13216-13219	red	_	
74-19	13219-13220	)	_	
74-20	13221-13224	but	_	
74-21	13225-13234	decreased	_	
74-22	13235-13239	ReHo	_	
74-23	13240-13242	in	_	
74-24	13243-13246	the	_	
74-25	13247-13251	left	_	
74-26	13252-13267	parahippocampal	_	
74-27	13268-13273	gyrus	_	
74-28	13273-13274	,	_	
74-29	13275-13279	left	_	
74-30	13280-13286	middle	_	
74-31	13287-13295	temporal	_	
74-32	13296-13301	gyrus	_	
74-33	13301-13302	,	_	
74-34	13303-13308	right	_	
74-35	13309-13316	lingual	_	
74-36	13317-13322	gyrus	_	
74-37	13322-13323	,	_	
74-38	13324-13327	and	_	
74-39	13328-13337	precuneus	_	
74-40	13338-13339	(	_	
74-41	13339-13343	blue	_	
74-42	13343-13344	)	_	
74-43	13344-13345	.	_	

#Text=(P < 0.05, corrected)
#Text=Brain regions with abnormal ReHo in heroin relapse and non-relapse patients under MMT
#Text=Brain area\tSide\tMean ReHo\tBA\tMNI coordinate (mm)\tVoxels\tT value (voxel-level)\t \tNon-relapser\tRelapser\tx\ty\tz\t \tOrbitofrontal cortex\tR\t0.32 ± 0.49\t0.32 ± 0.76\t11\t20\t54\t12\t18\t3.28\t \tOrbitofrontal cortex\tL\t−0.20 ± 0.17\t−0.01 ± 0.20\t11\t−33\t54\t18\t16\t3.25\t \tCaudate nucleus\tR\t0.60 ± 0.53\t1.10 ± 0.31\t40\t15\t12\t9\t32\t3.68\t \tCerebellum\tR\t−0.97 ± 0.64\t−0.27 ± 0.62\t22\t45\t−51\t−39\t22\t3.48\t \tParahippocampal gyrus\tL\t−0.83 ± 0.58\t−1.57 ± 0.55\t34\t−12\t−12\t−24\t7\t−4.11\t \tLingual gyrus\tR\t0.60 ± 0.51\t−0.20 ± 0.56\t19\t21\t−51\t3\t51\t−4.68\t \tPrecuneus\tR\t0.60 ± 0.51\t−0.20 ± 0.56\t18\t21\t−51\t3\t10\t−4.68\t \tMiddle temporal gyrus\tL\t0.20 ± 0.40\t−0.44 ± 0.61\t13\t−51\t−42\t9\t26\t−3.89\t \t
#Text=
#Text=Note: R right, L left, BA Brodmann area, MNI Montreal Neurological Institute
#Text=Compared with heroin non-relapsers, the relapsers showed significant increases of ReHo in the bilateral medial OFC, right caudate nucleus, and right cerebellum bilateral, but significant decreases of ReHo in the left parahippocampal gyrus, right lingual gyrus, right precuneus, and left middle temporal gyrus (Fig. 1 and Table 2).
75-1	13346-13347	(	_	
75-2	13347-13348	P	_	
75-3	13349-13350	<	_	
75-4	13351-13355	0.05	_	
75-5	13355-13356	,	_	
75-6	13357-13366	corrected	_	
75-7	13366-13367	)	_	
75-8	13368-13373	Brain	_	
75-9	13374-13381	regions	_	
75-10	13382-13386	with	_	
75-11	13387-13395	abnormal	_	
75-12	13396-13400	ReHo	_	
75-13	13401-13403	in	_	
75-14	13404-13410	heroin	_	
75-15	13411-13418	relapse	_	
75-16	13419-13422	and	_	
75-17	13423-13434	non-relapse	_	
75-18	13435-13443	patients	_	
75-19	13444-13449	under	_	
75-20	13450-13453	MMT	_	
75-21	13454-13459	Brain	_	
75-22	13460-13464	area	_	
75-23	13465-13469	Side	_	
75-24	13470-13474	Mean	_	
75-25	13475-13479	ReHo	_	
75-26	13480-13482	BA	_	
75-27	13483-13486	MNI	_	
75-28	13487-13497	coordinate	_	
75-29	13498-13499	(	_	
75-30	13499-13501	mm	_	
75-31	13501-13502	)	_	
75-32	13503-13509	Voxels	_	
75-33	13510-13511	T	_	
75-34	13512-13517	value	_	
75-35	13518-13519	(	_	
75-36	13519-13530	voxel-level	_	
75-37	13530-13531	)	_	
75-38	13534-13546	Non-relapser	_	
75-39	13547-13555	Relapser	_	
75-40	13556-13557	x	_	
75-41	13558-13559	y	_	
75-42	13560-13561	z	_	
75-43	13564-13577	Orbitofrontal	_	
75-44	13578-13584	cortex	_	
75-45	13585-13586	R	_	
75-46	13587-13591	0.32	_	
75-47	13592-13593	±	_	
75-48	13594-13598	0.49	_	
75-49	13599-13603	0.32	_	
75-50	13604-13605	±	_	
75-51	13606-13610	0.76	_	
75-52	13611-13613	11	_	
75-53	13614-13616	20	_	
75-54	13617-13619	54	_	
75-55	13620-13622	12	_	
75-56	13623-13625	18	_	
75-57	13626-13630	3.28	_	
75-58	13633-13646	Orbitofrontal	_	
75-59	13647-13653	cortex	_	
75-60	13654-13655	L	_	
75-61	13656-13657	−	_	
75-62	13657-13661	0.20	_	
75-63	13662-13663	±	_	
75-64	13664-13668	0.17	_	
75-65	13669-13670	−	_	
75-66	13670-13674	0.01	_	
75-67	13675-13676	±	_	
75-68	13677-13681	0.20	_	
75-69	13682-13684	11	_	
75-70	13685-13686	−	_	
75-71	13686-13688	33	_	
75-72	13689-13691	54	_	
75-73	13692-13694	18	_	
75-74	13695-13697	16	_	
75-75	13698-13702	3.25	_	
75-76	13705-13712	Caudate	_	
75-77	13713-13720	nucleus	_	
75-78	13721-13722	R	_	
75-79	13723-13727	0.60	_	
75-80	13728-13729	±	_	
75-81	13730-13734	0.53	_	
75-82	13735-13739	1.10	_	
75-83	13740-13741	±	_	
75-84	13742-13746	0.31	_	
75-85	13747-13749	40	_	
75-86	13750-13752	15	_	
75-87	13753-13755	12	_	
75-88	13756-13757	9	_	
75-89	13758-13760	32	_	
75-90	13761-13765	3.68	_	
75-91	13768-13778	Cerebellum	_	
75-92	13779-13780	R	_	
75-93	13781-13782	−	_	
75-94	13782-13786	0.97	_	
75-95	13787-13788	±	_	
75-96	13789-13793	0.64	_	
75-97	13794-13795	−	_	
75-98	13795-13799	0.27	_	
75-99	13800-13801	±	_	
75-100	13802-13806	0.62	_	
75-101	13807-13809	22	_	
75-102	13810-13812	45	_	
75-103	13813-13814	−	_	
75-104	13814-13816	51	_	
75-105	13817-13818	−	_	
75-106	13818-13820	39	_	
75-107	13821-13823	22	_	
75-108	13824-13828	3.48	_	
75-109	13831-13846	Parahippocampal	_	
75-110	13847-13852	gyrus	_	
75-111	13853-13854	L	_	
75-112	13855-13856	−	_	
75-113	13856-13860	0.83	_	
75-114	13861-13862	±	_	
75-115	13863-13867	0.58	_	
75-116	13868-13869	−	_	
75-117	13869-13873	1.57	_	
75-118	13874-13875	±	_	
75-119	13876-13880	0.55	_	
75-120	13881-13883	34	_	
75-121	13884-13885	−	_	
75-122	13885-13887	12	_	
75-123	13888-13889	−	_	
75-124	13889-13891	12	_	
75-125	13892-13893	−	_	
75-126	13893-13895	24	_	
75-127	13896-13897	7	_	
75-128	13898-13899	−	_	
75-129	13899-13903	4.11	_	
75-130	13906-13913	Lingual	_	
75-131	13914-13919	gyrus	_	
75-132	13920-13921	R	_	
75-133	13922-13926	0.60	_	
75-134	13927-13928	±	_	
75-135	13929-13933	0.51	_	
75-136	13934-13935	−	_	
75-137	13935-13939	0.20	_	
75-138	13940-13941	±	_	
75-139	13942-13946	0.56	_	
75-140	13947-13949	19	_	
75-141	13950-13952	21	_	
75-142	13953-13954	−	_	
75-143	13954-13956	51	_	
75-144	13957-13958	3	_	
75-145	13959-13961	51	_	
75-146	13962-13963	−	_	
75-147	13963-13967	4.68	_	
75-148	13970-13979	Precuneus	_	
75-149	13980-13981	R	_	
75-150	13982-13986	0.60	_	
75-151	13987-13988	±	_	
75-152	13989-13993	0.51	_	
75-153	13994-13995	−	_	
75-154	13995-13999	0.20	_	
75-155	14000-14001	±	_	
75-156	14002-14006	0.56	_	
75-157	14007-14009	18	_	
75-158	14010-14012	21	_	
75-159	14013-14014	−	_	
75-160	14014-14016	51	_	
75-161	14017-14018	3	_	
75-162	14019-14021	10	_	
75-163	14022-14023	−	_	
75-164	14023-14027	4.68	_	
75-165	14030-14036	Middle	_	
75-166	14037-14045	temporal	_	
75-167	14046-14051	gyrus	_	
75-168	14052-14053	L	_	
75-169	14054-14058	0.20	_	
75-170	14059-14060	±	_	
75-171	14061-14065	0.40	_	
75-172	14066-14067	−	_	
75-173	14067-14071	0.44	_	
75-174	14072-14073	±	_	
75-175	14074-14078	0.61	_	
75-176	14079-14081	13	_	
75-177	14082-14083	−	_	
75-178	14083-14085	51	_	
75-179	14086-14087	−	_	
75-180	14087-14089	42	_	
75-181	14090-14091	9	_	
75-182	14092-14094	26	_	
75-183	14095-14096	−	_	
75-184	14096-14100	3.89	_	
75-185	14105-14109	Note	_	
75-186	14109-14110	:	_	
75-187	14111-14112	R	_	
75-188	14113-14118	right	_	
75-189	14118-14119	,	_	
75-190	14120-14121	L	_	
75-191	14122-14126	left	_	
75-192	14126-14127	,	_	
75-193	14128-14130	BA	_	
75-194	14131-14139	Brodmann	_	
75-195	14140-14144	area	_	
75-196	14144-14145	,	_	
75-197	14146-14149	MNI	_	
75-198	14150-14158	Montreal	_	
75-199	14159-14171	Neurological	_	
75-200	14172-14181	Institute	_	
75-201	14182-14190	Compared	_	
75-202	14191-14195	with	_	
75-203	14196-14202	heroin	_	
75-204	14203-14216	non-relapsers	_	
75-205	14216-14217	,	_	
75-206	14218-14221	the	_	
75-207	14222-14231	relapsers	_	
75-208	14232-14238	showed	_	
75-209	14239-14250	significant	_	
75-210	14251-14260	increases	_	
75-211	14261-14263	of	_	
75-212	14264-14268	ReHo	_	
75-213	14269-14271	in	_	
75-214	14272-14275	the	_	
75-215	14276-14285	bilateral	_	
75-216	14286-14292	medial	_	
75-217	14293-14296	OFC	_	
75-218	14296-14297	,	_	
75-219	14298-14303	right	_	
75-220	14304-14311	caudate	_	
75-221	14312-14319	nucleus	_	
75-222	14319-14320	,	_	
75-223	14321-14324	and	_	
75-224	14325-14330	right	_	
75-225	14331-14341	cerebellum	_	
75-226	14342-14351	bilateral	_	
75-227	14351-14352	,	_	
75-228	14353-14356	but	_	
75-229	14357-14368	significant	_	
75-230	14369-14378	decreases	_	
75-231	14379-14381	of	_	
75-232	14382-14386	ReHo	_	
75-233	14387-14389	in	_	
75-234	14390-14393	the	_	
75-235	14394-14398	left	_	
75-236	14399-14414	parahippocampal	_	
75-237	14415-14420	gyrus	_	
75-238	14420-14421	,	_	
75-239	14422-14427	right	_	
75-240	14428-14435	lingual	_	
75-241	14436-14441	gyrus	_	
75-242	14441-14442	,	_	
75-243	14443-14448	right	_	
75-244	14449-14458	precuneus	_	
75-245	14458-14459	,	_	
75-246	14460-14463	and	_	
75-247	14464-14468	left	_	
75-248	14469-14475	middle	_	
75-249	14476-14484	temporal	_	
75-250	14485-14490	gyrus	_	
75-251	14491-14492	(	_	
75-252	14492-14495	Fig	_	
75-253	14495-14496	.	_	
75-254	14496-14497	 	_	
75-255	14497-14498	1	_	
75-256	14499-14502	and	_	
75-257	14503-14508	Table	_	
75-258	14508-14509	 	_	
75-259	14509-14510	2	_	
75-260	14510-14511	)	_	
75-261	14511-14512	.	_	

#Text=Spearman correlation between mean ReHo of abnormal brain regions and relapse rate in relapse patients
#Text=Brain area\tSide\tMNI Coordinate (mm)\tCorrelation coefficient\tCorrected p value\t \tx\ty\tz\t \tOrbitofrontal cortex\tR\t20\t54\t12\t−0.169\t0.084\t \tOrbitofrontal cortex\tL\t−33\t54\t18\t−0.176\t0.056\t \tCaudate nucleus\tR\t15\t12\t9\t0.380\t0.018*\t \tCerebellum\tR\t45\t−51\t−39\t−0.040\t0.108\t \tParahippocampus gyrus\tL\t−12\t−12\t−24\t−0.099\t0.083\t \tLingual gyrus\tR\t21\t−51\t3\t0.012\t0.120\t \tPrecuneus\tR\t21\t−51\t3\t0.014\t0.106\t \tMiddle temporal gyrus\tL\t−51\t−42\t9\t−0.076\t0.093\t \t
#Text=
#Text=Note: R right, L left, BA Brodmann area, MNI Montreal Neurological Institute
#Text=The significance for correlation coefficients was corrected by Bonferroni’s test. p value was set as 0.05. *, p < 0.05
#Text=Spearman correlation between mean ReHo of abnormal brain regions and subjective heroin craving in relapse patients
#Text=Brain area\tSide\tMNI coordinate (mm)\tCorrelation coefficient\tCorrected p value\t \tx\ty\tz\t \tOrbitofrontal cortex\tR\t20\t54\t12\t−0.038\t0.109\t \tOrbitofrontal cortex\tL\t−33\t54\t18\t−0.101\t0.066\t \tCaudate nucleus\tR\t15\t12\t9\t0.395\t0.010*\t \tCerebellum\tR\t45\t−51\t−39\t0.082\t0.078\t \tParahippocampus gyrus\tL\t−12\t−12\t−24\t0.056\t0.101\t \tLingual gyrus\tR\t21\t−51\t3\t−0.093\t0.086\t \tPrecuneus\tR\t21\t−51\t3\t−0.108\t0.071\t \tMiddle temporal gyrus\tL\t−51\t−42\t9\t0.020\t0.116\t \t
#Text=
#Text=Note: R right, L left, BA Brodmann area, MNI Montreal Neurological Institute
#Text=The significance for correlation coefficients was corrected by Bonferroni’s test. p value was set as 0.05. *, p < 0.05
#Text=We then analyzed the association of altered ReHo values in the identified regions (including bilateral medial OFC, right caudate, right cerebellum, left parahippocampal gyrus, left middle temporal gyrus, right lingual gyrus, and right precuneus) with relapse rates or with subjective heroin craving in relapse patients.
76-1	14513-14521	Spearman	_	
76-2	14522-14533	correlation	_	
76-3	14534-14541	between	_	
76-4	14542-14546	mean	_	
76-5	14547-14551	ReHo	_	
76-6	14552-14554	of	_	
76-7	14555-14563	abnormal	_	
76-8	14564-14569	brain	_	
76-9	14570-14577	regions	_	
76-10	14578-14581	and	_	
76-11	14582-14589	relapse	_	
76-12	14590-14594	rate	_	
76-13	14595-14597	in	_	
76-14	14598-14605	relapse	_	
76-15	14606-14614	patients	_	
76-16	14615-14620	Brain	_	
76-17	14621-14625	area	_	
76-18	14626-14630	Side	_	
76-19	14631-14634	MNI	_	
76-20	14635-14645	Coordinate	_	
76-21	14646-14647	(	_	
76-22	14647-14649	mm	_	
76-23	14649-14650	)	_	
76-24	14651-14662	Correlation	_	
76-25	14663-14674	coefficient	_	
76-26	14675-14684	Corrected	_	
76-27	14685-14686	p	_	
76-28	14687-14692	value	_	
76-29	14695-14696	x	_	
76-30	14697-14698	y	_	
76-31	14699-14700	z	_	
76-32	14703-14716	Orbitofrontal	_	
76-33	14717-14723	cortex	_	
76-34	14724-14725	R	_	
76-35	14726-14728	20	_	
76-36	14729-14731	54	_	
76-37	14732-14734	12	_	
76-38	14735-14736	−	_	
76-39	14736-14741	0.169	_	
76-40	14742-14747	0.084	_	
76-41	14750-14763	Orbitofrontal	_	
76-42	14764-14770	cortex	_	
76-43	14771-14772	L	_	
76-44	14773-14774	−	_	
76-45	14774-14776	33	_	
76-46	14777-14779	54	_	
76-47	14780-14782	18	_	
76-48	14783-14784	−	_	
76-49	14784-14789	0.176	_	
76-50	14790-14795	0.056	_	
76-51	14798-14805	Caudate	_	
76-52	14806-14813	nucleus	_	
76-53	14814-14815	R	_	
76-54	14816-14818	15	_	
76-55	14819-14821	12	_	
76-56	14822-14823	9	_	
76-57	14824-14829	0.380	_	
76-58	14830-14835	0.018	_	
76-59	14835-14836	*	_	
76-60	14839-14849	Cerebellum	_	
76-61	14850-14851	R	_	
76-62	14852-14854	45	_	
76-63	14855-14856	−	_	
76-64	14856-14858	51	_	
76-65	14859-14860	−	_	
76-66	14860-14862	39	_	
76-67	14863-14864	−	_	
76-68	14864-14869	0.040	_	
76-69	14870-14875	0.108	_	
76-70	14878-14893	Parahippocampus	_	
76-71	14894-14899	gyrus	_	
76-72	14900-14901	L	_	
76-73	14902-14903	−	_	
76-74	14903-14905	12	_	
76-75	14906-14907	−	_	
76-76	14907-14909	12	_	
76-77	14910-14911	−	_	
76-78	14911-14913	24	_	
76-79	14914-14915	−	_	
76-80	14915-14920	0.099	_	
76-81	14921-14926	0.083	_	
76-82	14929-14936	Lingual	_	
76-83	14937-14942	gyrus	_	
76-84	14943-14944	R	_	
76-85	14945-14947	21	_	
76-86	14948-14949	−	_	
76-87	14949-14951	51	_	
76-88	14952-14953	3	_	
76-89	14954-14959	0.012	_	
76-90	14960-14965	0.120	_	
76-91	14968-14977	Precuneus	_	
76-92	14978-14979	R	_	
76-93	14980-14982	21	_	
76-94	14983-14984	−	_	
76-95	14984-14986	51	_	
76-96	14987-14988	3	_	
76-97	14989-14994	0.014	_	
76-98	14995-15000	0.106	_	
76-99	15003-15009	Middle	_	
76-100	15010-15018	temporal	_	
76-101	15019-15024	gyrus	_	
76-102	15025-15026	L	_	
76-103	15027-15028	−	_	
76-104	15028-15030	51	_	
76-105	15031-15032	−	_	
76-106	15032-15034	42	_	
76-107	15035-15036	9	_	
76-108	15037-15038	−	_	
76-109	15038-15043	0.076	_	
76-110	15044-15049	0.093	_	
76-111	15054-15058	Note	_	
76-112	15058-15059	:	_	
76-113	15060-15061	R	_	
76-114	15062-15067	right	_	
76-115	15067-15068	,	_	
76-116	15069-15070	L	_	
76-117	15071-15075	left	_	
76-118	15075-15076	,	_	
76-119	15077-15079	BA	_	
76-120	15080-15088	Brodmann	_	
76-121	15089-15093	area	_	
76-122	15093-15094	,	_	
76-123	15095-15098	MNI	_	
76-124	15099-15107	Montreal	_	
76-125	15108-15120	Neurological	_	
76-126	15121-15130	Institute	_	
76-127	15131-15134	The	_	
76-128	15135-15147	significance	_	
76-129	15148-15151	for	_	
76-130	15152-15163	correlation	_	
76-131	15164-15176	coefficients	_	
76-132	15177-15180	was	_	
76-133	15181-15190	corrected	_	
76-134	15191-15193	by	_	
76-135	15194-15204	Bonferroni	_	
76-136	15204-15205	’	_	
76-137	15205-15206	s	_	
76-138	15207-15211	test	_	
76-139	15211-15212	.	_	
76-140	15213-15214	p	_	
76-141	15215-15220	value	_	
76-142	15221-15224	was	_	
76-143	15225-15228	set	_	
76-144	15229-15231	as	_	
76-145	15232-15236	0.05	_	
76-146	15236-15237	.	_	
76-147	15238-15239	*	_	
76-148	15239-15240	,	_	
76-149	15241-15242	p	_	
76-150	15243-15244	<	_	
76-151	15245-15249	0.05	_	
76-152	15250-15258	Spearman	_	
76-153	15259-15270	correlation	_	
76-154	15271-15278	between	_	
76-155	15279-15283	mean	_	
76-156	15284-15288	ReHo	_	
76-157	15289-15291	of	_	
76-158	15292-15300	abnormal	_	
76-159	15301-15306	brain	_	
76-160	15307-15314	regions	_	
76-161	15315-15318	and	_	
76-162	15319-15329	subjective	_	
76-163	15330-15336	heroin	_	
76-164	15337-15344	craving	_	
76-165	15345-15347	in	_	
76-166	15348-15355	relapse	_	
76-167	15356-15364	patients	_	
76-168	15365-15370	Brain	_	
76-169	15371-15375	area	_	
76-170	15376-15380	Side	_	
76-171	15381-15384	MNI	_	
76-172	15385-15395	coordinate	_	
76-173	15396-15397	(	_	
76-174	15397-15399	mm	_	
76-175	15399-15400	)	_	
76-176	15401-15412	Correlation	_	
76-177	15413-15424	coefficient	_	
76-178	15425-15434	Corrected	_	
76-179	15435-15436	p	_	
76-180	15437-15442	value	_	
76-181	15445-15446	x	_	
76-182	15447-15448	y	_	
76-183	15449-15450	z	_	
76-184	15453-15466	Orbitofrontal	_	
76-185	15467-15473	cortex	_	
76-186	15474-15475	R	_	
76-187	15476-15478	20	_	
76-188	15479-15481	54	_	
76-189	15482-15484	12	_	
76-190	15485-15486	−	_	
76-191	15486-15491	0.038	_	
76-192	15492-15497	0.109	_	
76-193	15500-15513	Orbitofrontal	_	
76-194	15514-15520	cortex	_	
76-195	15521-15522	L	_	
76-196	15523-15524	−	_	
76-197	15524-15526	33	_	
76-198	15527-15529	54	_	
76-199	15530-15532	18	_	
76-200	15533-15534	−	_	
76-201	15534-15539	0.101	_	
76-202	15540-15545	0.066	_	
76-203	15548-15555	Caudate	_	
76-204	15556-15563	nucleus	_	
76-205	15564-15565	R	_	
76-206	15566-15568	15	_	
76-207	15569-15571	12	_	
76-208	15572-15573	9	_	
76-209	15574-15579	0.395	_	
76-210	15580-15585	0.010	_	
76-211	15585-15586	*	_	
76-212	15589-15599	Cerebellum	_	
76-213	15600-15601	R	_	
76-214	15602-15604	45	_	
76-215	15605-15606	−	_	
76-216	15606-15608	51	_	
76-217	15609-15610	−	_	
76-218	15610-15612	39	_	
76-219	15613-15618	0.082	_	
76-220	15619-15624	0.078	_	
76-221	15627-15642	Parahippocampus	_	
76-222	15643-15648	gyrus	_	
76-223	15649-15650	L	_	
76-224	15651-15652	−	_	
76-225	15652-15654	12	_	
76-226	15655-15656	−	_	
76-227	15656-15658	12	_	
76-228	15659-15660	−	_	
76-229	15660-15662	24	_	
76-230	15663-15668	0.056	_	
76-231	15669-15674	0.101	_	
76-232	15677-15684	Lingual	_	
76-233	15685-15690	gyrus	_	
76-234	15691-15692	R	_	
76-235	15693-15695	21	_	
76-236	15696-15697	−	_	
76-237	15697-15699	51	_	
76-238	15700-15701	3	_	
76-239	15702-15703	−	_	
76-240	15703-15708	0.093	_	
76-241	15709-15714	0.086	_	
76-242	15717-15726	Precuneus	_	
76-243	15727-15728	R	_	
76-244	15729-15731	21	_	
76-245	15732-15733	−	_	
76-246	15733-15735	51	_	
76-247	15736-15737	3	_	
76-248	15738-15739	−	_	
76-249	15739-15744	0.108	_	
76-250	15745-15750	0.071	_	
76-251	15753-15759	Middle	_	
76-252	15760-15768	temporal	_	
76-253	15769-15774	gyrus	_	
76-254	15775-15776	L	_	
76-255	15777-15778	−	_	
76-256	15778-15780	51	_	
76-257	15781-15782	−	_	
76-258	15782-15784	42	_	
76-259	15785-15786	9	_	
76-260	15787-15792	0.020	_	
76-261	15793-15798	0.116	_	
76-262	15803-15807	Note	_	
76-263	15807-15808	:	_	
76-264	15809-15810	R	_	
76-265	15811-15816	right	_	
76-266	15816-15817	,	_	
76-267	15818-15819	L	_	
76-268	15820-15824	left	_	
76-269	15824-15825	,	_	
76-270	15826-15828	BA	_	
76-271	15829-15837	Brodmann	_	
76-272	15838-15842	area	_	
76-273	15842-15843	,	_	
76-274	15844-15847	MNI	_	
76-275	15848-15856	Montreal	_	
76-276	15857-15869	Neurological	_	
76-277	15870-15879	Institute	_	
76-278	15880-15883	The	_	
76-279	15884-15896	significance	_	
76-280	15897-15900	for	_	
76-281	15901-15912	correlation	_	
76-282	15913-15925	coefficients	_	
76-283	15926-15929	was	_	
76-284	15930-15939	corrected	_	
76-285	15940-15942	by	_	
76-286	15943-15953	Bonferroni	_	
76-287	15953-15954	’	_	
76-288	15954-15955	s	_	
76-289	15956-15960	test	_	
76-290	15960-15961	.	_	
76-291	15962-15963	p	_	
76-292	15964-15969	value	_	
76-293	15970-15973	was	_	
76-294	15974-15977	set	_	
76-295	15978-15980	as	_	
76-296	15981-15985	0.05	_	
76-297	15985-15986	.	_	
76-298	15987-15988	*	_	
76-299	15988-15989	,	_	
76-300	15990-15991	p	_	
76-301	15992-15993	<	_	
76-302	15994-15998	0.05	_	
76-303	15999-16001	We	_	
76-304	16002-16006	then	_	
76-305	16007-16015	analyzed	_	
76-306	16016-16019	the	_	
76-307	16020-16031	association	_	
76-308	16032-16034	of	_	
76-309	16035-16042	altered	_	
76-310	16043-16047	ReHo	_	
76-311	16048-16054	values	_	
76-312	16055-16057	in	_	
76-313	16058-16061	the	_	
76-314	16062-16072	identified	_	
76-315	16073-16080	regions	_	
76-316	16081-16082	(	_	
76-317	16082-16091	including	_	
76-318	16092-16101	bilateral	_	
76-319	16102-16108	medial	_	
76-320	16109-16112	OFC	_	
76-321	16112-16113	,	_	
76-322	16114-16119	right	_	
76-323	16120-16127	caudate	_	
76-324	16127-16128	,	_	
76-325	16129-16134	right	_	
76-326	16135-16145	cerebellum	_	
76-327	16145-16146	,	_	
76-328	16147-16151	left	_	
76-329	16152-16167	parahippocampal	_	
76-330	16168-16173	gyrus	_	
76-331	16173-16174	,	_	
76-332	16175-16179	left	_	
76-333	16180-16186	middle	_	
76-334	16187-16195	temporal	_	
76-335	16196-16201	gyrus	_	
76-336	16201-16202	,	_	
76-337	16203-16208	right	_	
76-338	16209-16216	lingual	_	
76-339	16217-16222	gyrus	_	
76-340	16222-16223	,	_	
76-341	16224-16227	and	_	
76-342	16228-16233	right	_	
76-343	16234-16243	precuneus	_	
76-344	16243-16244	)	_	
76-345	16245-16249	with	_	
76-346	16250-16257	relapse	_	
76-347	16258-16263	rates	_	
76-348	16264-16266	or	_	
76-349	16267-16271	with	_	
76-350	16272-16282	subjective	_	
76-351	16283-16289	heroin	_	
76-352	16290-16297	craving	_	
76-353	16298-16300	in	_	
76-354	16301-16308	relapse	_	
76-355	16309-16317	patients	_	
76-356	16317-16318	.	_	

#Text=Our results showed a positive correlation was observed between mean ReHo values in the right caudate and relapse rates or heroin craving whereas no correlation relationships were found between ReHo values and other brain regions (Tables 3 and 4).
77-1	16319-16322	Our	_	
77-2	16323-16330	results	_	
77-3	16331-16337	showed	_	
77-4	16338-16339	a	_	
77-5	16340-16348	positive	_	
77-6	16349-16360	correlation	_	
77-7	16361-16364	was	_	
77-8	16365-16373	observed	_	
77-9	16374-16381	between	_	
77-10	16382-16386	mean	_	
77-11	16387-16391	ReHo	_	
77-12	16392-16398	values	_	
77-13	16399-16401	in	_	
77-14	16402-16405	the	_	
77-15	16406-16411	right	_	
77-16	16412-16419	caudate	_	
77-17	16420-16423	and	_	
77-18	16424-16431	relapse	_	
77-19	16432-16437	rates	_	
77-20	16438-16440	or	_	
77-21	16441-16447	heroin	_	
77-22	16448-16455	craving	_	
77-23	16456-16463	whereas	_	
77-24	16464-16466	no	_	
77-25	16467-16478	correlation	_	
77-26	16479-16492	relationships	_	
77-27	16493-16497	were	_	
77-28	16498-16503	found	_	
77-29	16504-16511	between	_	
77-30	16512-16516	ReHo	_	
77-31	16517-16523	values	_	
77-32	16524-16527	and	_	
77-33	16528-16533	other	_	
77-34	16534-16539	brain	_	
77-35	16540-16547	regions	_	
77-36	16548-16549	(	_	
77-37	16549-16555	Tables	_	
77-38	16555-16556	 	_	
77-39	16556-16557	3	_	
77-40	16558-16561	and	_	
77-41	16562-16563	4	_	
77-42	16563-16564	)	_	
77-43	16564-16565	.	_	

#Text=Additionally, we also made the correlation between the amount of motion in each subject and the ReHo values, and found a negative result (data not shown), indicating that head motion was not biasing the ReHo.
78-1	16566-16578	Additionally	_	
78-2	16578-16579	,	_	
78-3	16580-16582	we	_	
78-4	16583-16587	also	_	
78-5	16588-16592	made	_	
78-6	16593-16596	the	_	
78-7	16597-16608	correlation	_	
78-8	16609-16616	between	_	
78-9	16617-16620	the	_	
78-10	16621-16627	amount	_	
78-11	16628-16630	of	_	
78-12	16631-16637	motion	_	
78-13	16638-16640	in	_	
78-14	16641-16645	each	_	
78-15	16646-16653	subject	_	
78-16	16654-16657	and	_	
78-17	16658-16661	the	_	
78-18	16662-16666	ReHo	_	
78-19	16667-16673	values	_	
78-20	16673-16674	,	_	
78-21	16675-16678	and	_	
78-22	16679-16684	found	_	
78-23	16685-16686	a	_	
78-24	16687-16695	negative	_	
78-25	16696-16702	result	_	
78-26	16703-16704	(	_	
78-27	16704-16708	data	_	
78-28	16709-16712	not	_	
78-29	16713-16718	shown	_	
78-30	16718-16719	)	_	
78-31	16719-16720	,	_	
78-32	16721-16731	indicating	_	
78-33	16732-16736	that	_	
78-34	16737-16741	head	_	
78-35	16742-16748	motion	_	
78-36	16749-16752	was	_	
78-37	16753-16756	not	_	
78-38	16757-16764	biasing	_	
78-39	16765-16768	the	_	
78-40	16769-16773	ReHo	_	
78-41	16773-16774	.	_	

#Text=Discussion
#Text=In this study we carried out a 12-month follow-up study using resting-state fMRI by analysis of brain regions with abnormal ReHo in heroin relapsers under MMT, and found that compared with the non-relapsers, an increased ReHo values were evident in the bilateral medial OFC, right caudate nucleus, and right cerebellum of the heroin relapsers while a decreased ReHo in the left parahippocampal gyrus, left middle temporal gyrus, right lingual gyrus, and precuneus.
79-1	16775-16785	Discussion	_	
79-2	16786-16788	In	_	
79-3	16789-16793	this	_	
79-4	16794-16799	study	_	
79-5	16800-16802	we	_	
79-6	16803-16810	carried	_	
79-7	16811-16814	out	_	
79-8	16815-16816	a	_	
79-9	16817-16819	12	_	
79-10	16819-16820	-	_	
79-11	16820-16825	month	_	
79-12	16826-16835	follow-up	_	
79-13	16836-16841	study	_	
79-14	16842-16847	using	_	
79-15	16848-16861	resting-state	_	
79-16	16862-16866	fMRI	_	
79-17	16867-16869	by	_	
79-18	16870-16878	analysis	_	
79-19	16879-16881	of	_	
79-20	16882-16887	brain	_	
79-21	16888-16895	regions	_	
79-22	16896-16900	with	_	
79-23	16901-16909	abnormal	_	
79-24	16910-16914	ReHo	_	
79-25	16915-16917	in	_	
79-26	16918-16924	heroin	_	
79-27	16925-16934	relapsers	_	
79-28	16935-16940	under	_	
79-29	16941-16944	MMT	_	
79-30	16944-16945	,	_	
79-31	16946-16949	and	_	
79-32	16950-16955	found	_	
79-33	16956-16960	that	_	
79-34	16961-16969	compared	_	
79-35	16970-16974	with	_	
79-36	16975-16978	the	_	
79-37	16979-16992	non-relapsers	_	
79-38	16992-16993	,	_	
79-39	16994-16996	an	_	
79-40	16997-17006	increased	_	
79-41	17007-17011	ReHo	_	
79-42	17012-17018	values	_	
79-43	17019-17023	were	_	
79-44	17024-17031	evident	_	
79-45	17032-17034	in	_	
79-46	17035-17038	the	_	
79-47	17039-17048	bilateral	_	
79-48	17049-17055	medial	_	
79-49	17056-17059	OFC	_	
79-50	17059-17060	,	_	
79-51	17061-17066	right	_	
79-52	17067-17074	caudate	_	
79-53	17075-17082	nucleus	_	
79-54	17082-17083	,	_	
79-55	17084-17087	and	_	
79-56	17088-17093	right	_	
79-57	17094-17104	cerebellum	_	
79-58	17105-17107	of	_	
79-59	17108-17111	the	_	
79-60	17112-17118	heroin	_	
79-61	17119-17128	relapsers	_	
79-62	17129-17134	while	_	
79-63	17135-17136	a	_	
79-64	17137-17146	decreased	_	
79-65	17147-17151	ReHo	_	
79-66	17152-17154	in	_	
79-67	17155-17158	the	_	
79-68	17159-17163	left	_	
79-69	17164-17179	parahippocampal	_	
79-70	17180-17185	gyrus	_	
79-71	17185-17186	,	_	
79-72	17187-17191	left	_	
79-73	17192-17198	middle	_	
79-74	17199-17207	temporal	_	
79-75	17208-17213	gyrus	_	
79-76	17213-17214	,	_	
79-77	17215-17220	right	_	
79-78	17221-17228	lingual	_	
79-79	17229-17234	gyrus	_	
79-80	17234-17235	,	_	
79-81	17236-17239	and	_	
79-82	17240-17249	precuneus	_	
79-83	17249-17250	.	_	

#Text=Moreover, ReHo values in right caudate nucleus were correlated with relapse rates or subjective heroin-craving response.
80-1	17251-17259	Moreover	_	
80-2	17259-17260	,	_	
80-3	17261-17265	ReHo	_	
80-4	17266-17272	values	_	
80-5	17273-17275	in	_	
80-6	17276-17281	right	_	
80-7	17282-17289	caudate	_	
80-8	17290-17297	nucleus	_	
80-9	17298-17302	were	_	
80-10	17303-17313	correlated	_	
80-11	17314-17318	with	_	
80-12	17319-17326	relapse	_	
80-13	17327-17332	rates	_	
80-14	17333-17335	or	_	
80-15	17336-17346	subjective	_	
80-16	17347-17361	heroin-craving	_	
80-17	17362-17370	response	_	
80-18	17370-17371	.	_	

#Text=The medial OFC is a part of the limbic system, and is a functionally heterogeneous region that involved in complex adaptive behaviors.
81-1	17372-17375	The	_	
81-2	17376-17382	medial	_	
81-3	17383-17386	OFC	_	
81-4	17387-17389	is	_	
81-5	17390-17391	a	_	
81-6	17392-17396	part	_	
81-7	17397-17399	of	_	
81-8	17400-17403	the	_	
81-9	17404-17410	limbic	_	
81-10	17411-17417	system	_	
81-11	17417-17418	,	_	
81-12	17419-17422	and	_	
81-13	17423-17425	is	_	
81-14	17426-17427	a	_	
81-15	17428-17440	functionally	_	
81-16	17441-17454	heterogeneous	_	
81-17	17455-17461	region	_	
81-18	17462-17466	that	_	
81-19	17467-17475	involved	_	
81-20	17476-17478	in	_	
81-21	17479-17486	complex	_	
81-22	17487-17495	adaptive	_	
81-23	17496-17505	behaviors	_	
81-24	17505-17506	.	_	

#Text=It was reported that in active cocaine abusers, OFC was hypermetabolic in proportion to the intensity of the craving experienced by the subjects but was hypoactive in drug-addicted subjects tested during withdrawal.
82-1	17507-17509	It	_	
82-2	17510-17513	was	_	
82-3	17514-17522	reported	_	
82-4	17523-17527	that	_	
82-5	17528-17530	in	_	
82-6	17531-17537	active	_	
82-7	17538-17545	cocaine	_	
82-8	17546-17553	abusers	_	
82-9	17553-17554	,	_	
82-10	17555-17558	OFC	_	
82-11	17559-17562	was	_	
82-12	17563-17577	hypermetabolic	_	
82-13	17578-17580	in	_	
82-14	17581-17591	proportion	_	
82-15	17592-17594	to	_	
82-16	17595-17598	the	_	
82-17	17599-17608	intensity	_	
82-18	17609-17611	of	_	
82-19	17612-17615	the	_	
82-20	17616-17623	craving	_	
82-21	17624-17635	experienced	_	
82-22	17636-17638	by	_	
82-23	17639-17642	the	_	
82-24	17643-17651	subjects	_	
82-25	17652-17655	but	_	
82-26	17656-17659	was	_	
82-27	17660-17670	hypoactive	_	
82-28	17671-17673	in	_	
82-29	17674-17687	drug-addicted	_	
82-30	17688-17696	subjects	_	
82-31	17697-17703	tested	_	
82-32	17704-17710	during	_	
82-33	17711-17721	withdrawal	_	
82-34	17721-17722	.	_	

#Text=Increased OFC activation has also been associated with drug-related cues, and compulsive drug intake.
83-1	17723-17732	Increased	_	
83-2	17733-17736	OFC	_	
83-3	17737-17747	activation	_	
83-4	17748-17751	has	_	
83-5	17752-17756	also	_	
83-6	17757-17761	been	_	
83-7	17762-17772	associated	_	
83-8	17773-17777	with	_	
83-9	17778-17790	drug-related	_	
83-10	17791-17795	cues	_	
83-11	17795-17796	,	_	
83-12	17797-17800	and	_	
83-13	17801-17811	compulsive	_	
83-14	17812-17816	drug	_	
83-15	17817-17823	intake	_	
83-16	17823-17824	.	_	

#Text=Importantly, a preclinical study showed that damage to the OFC resulted in a behavioral compulsion to procure the reward even when it is no longer reinforced.
84-1	17825-17836	Importantly	_	
84-2	17836-17837	,	_	
84-3	17838-17839	a	_	
84-4	17840-17851	preclinical	_	
84-5	17852-17857	study	_	
84-6	17858-17864	showed	_	
84-7	17865-17869	that	_	
84-8	17870-17876	damage	_	
84-9	17877-17879	to	_	
84-10	17880-17883	the	_	
84-11	17884-17887	OFC	_	
84-12	17888-17896	resulted	_	
84-13	17897-17899	in	_	
84-14	17900-17901	a	_	
84-15	17902-17912	behavioral	_	
84-16	17913-17923	compulsion	_	
84-17	17924-17926	to	_	
84-18	17927-17934	procure	_	
84-19	17935-17938	the	_	
84-20	17939-17945	reward	_	
84-21	17946-17950	even	_	
84-22	17951-17955	when	_	
84-23	17956-17958	it	_	
84-24	17959-17961	is	_	
84-25	17962-17964	no	_	
84-26	17965-17971	longer	_	
84-27	17972-17982	reinforced	_	
84-28	17982-17983	.	_	

#Text=In the present study, we found increased ReHo in the bilateral medial OFC in the heroin relapsers under MMT, indicating an enhanced local synchronization of spontaneous low-frequency blood oxygenation level-dependent fluctuations in this region, and probably reflecting abnormalities of relapsers in the affective value of reinforcers, decision making and expectation.
85-1	17984-17986	In	_	
85-2	17987-17990	the	_	
85-3	17991-17998	present	_	
85-4	17999-18004	study	_	
85-5	18004-18005	,	_	
85-6	18006-18008	we	_	
85-7	18009-18014	found	_	
85-8	18015-18024	increased	_	
85-9	18025-18029	ReHo	_	
85-10	18030-18032	in	_	
85-11	18033-18036	the	_	
85-12	18037-18046	bilateral	_	
85-13	18047-18053	medial	_	
85-14	18054-18057	OFC	_	
85-15	18058-18060	in	_	
85-16	18061-18064	the	_	
85-17	18065-18071	heroin	_	
85-18	18072-18081	relapsers	_	
85-19	18082-18087	under	_	
85-20	18088-18091	MMT	_	
85-21	18091-18092	,	_	
85-22	18093-18103	indicating	_	
85-23	18104-18106	an	_	
85-24	18107-18115	enhanced	_	
85-25	18116-18121	local	_	
85-26	18122-18137	synchronization	_	
85-27	18138-18140	of	_	
85-28	18141-18152	spontaneous	_	
85-29	18153-18166	low-frequency	_	
85-30	18167-18172	blood	_	
85-31	18173-18184	oxygenation	_	
85-32	18185-18200	level-dependent	_	
85-33	18201-18213	fluctuations	_	
85-34	18214-18216	in	_	
85-35	18217-18221	this	_	
85-36	18222-18228	region	_	
85-37	18228-18229	,	_	
85-38	18230-18233	and	_	
85-39	18234-18242	probably	_	
85-40	18243-18253	reflecting	_	
85-41	18254-18267	abnormalities	_	
85-42	18268-18270	of	_	
85-43	18271-18280	relapsers	_	
85-44	18281-18283	in	_	
85-45	18284-18287	the	_	
85-46	18288-18297	affective	_	
85-47	18298-18303	value	_	
85-48	18304-18306	of	_	
85-49	18307-18318	reinforcers	_	
85-50	18318-18319	,	_	
85-51	18320-18328	decision	_	
85-52	18329-18335	making	_	
85-53	18336-18339	and	_	
85-54	18340-18351	expectation	_	
85-55	18351-18352	.	_	

#Text=Caudate nucleus (dorsal striatum) is a principal brain region of mesostriatum dopamine (DA) pathway and is recognized to contribute to drug addiction.
86-1	18353-18360	Caudate	_	
86-2	18361-18368	nucleus	_	
86-3	18369-18370	(	_	
86-4	18370-18376	dorsal	_	
86-5	18377-18385	striatum	_	
86-6	18385-18386	)	_	
86-7	18387-18389	is	_	
86-8	18390-18391	a	_	
86-9	18392-18401	principal	_	
86-10	18402-18407	brain	_	
86-11	18408-18414	region	_	
86-12	18415-18417	of	_	
86-13	18418-18430	mesostriatum	_	
86-14	18431-18439	dopamine	_	
86-15	18440-18441	(	_	
86-16	18441-18443	DA	_	
86-17	18443-18444	)	_	
86-18	18445-18452	pathway	_	
86-19	18453-18456	and	_	
86-20	18457-18459	is	_	
86-21	18460-18470	recognized	_	
86-22	18471-18473	to	_	
86-23	18474-18484	contribute	_	
86-24	18485-18487	to	_	
86-25	18488-18492	drug	_	
86-26	18493-18502	addiction	_	
86-27	18502-18503	.	_	

#Text=A group of study have demonstrated that in the caudate nucleus existed significant DA changes when addicts were exposed to drug-related cues, and the magnitude of these changes were correlated with self-reports of craving.
87-1	18504-18505	A	_	
87-2	18506-18511	group	_	
87-3	18512-18514	of	_	
87-4	18515-18520	study	_	
87-5	18521-18525	have	_	
87-6	18526-18538	demonstrated	_	
87-7	18539-18543	that	_	
87-8	18544-18546	in	_	
87-9	18547-18550	the	_	
87-10	18551-18558	caudate	_	
87-11	18559-18566	nucleus	_	
87-12	18567-18574	existed	_	
87-13	18575-18586	significant	_	
87-14	18587-18589	DA	_	
87-15	18590-18597	changes	_	
87-16	18598-18602	when	_	
87-17	18603-18610	addicts	_	
87-18	18611-18615	were	_	
87-19	18616-18623	exposed	_	
87-20	18624-18626	to	_	
87-21	18627-18639	drug-related	_	
87-22	18640-18644	cues	_	
87-23	18644-18645	,	_	
87-24	18646-18649	and	_	
87-25	18650-18653	the	_	
87-26	18654-18663	magnitude	_	
87-27	18664-18666	of	_	
87-28	18667-18672	these	_	
87-29	18673-18680	changes	_	
87-30	18681-18685	were	_	
87-31	18686-18696	correlated	_	
87-32	18697-18701	with	_	
87-33	18702-18714	self-reports	_	
87-34	18715-18717	of	_	
87-35	18718-18725	craving	_	
87-36	18725-18726	.	_	

#Text=For the drug-dependent patients, the enhanced activity in the caudate in response to drug-related cues indicated increased reward-based cognitive processes in the presence of the cues.
88-1	18727-18730	For	_	
88-2	18731-18734	the	_	
88-3	18735-18749	drug-dependent	_	
88-4	18750-18758	patients	_	
88-5	18758-18759	,	_	
88-6	18760-18763	the	_	
88-7	18764-18772	enhanced	_	
88-8	18773-18781	activity	_	
88-9	18782-18784	in	_	
88-10	18785-18788	the	_	
88-11	18789-18796	caudate	_	
88-12	18797-18799	in	_	
88-13	18800-18808	response	_	
88-14	18809-18811	to	_	
88-15	18812-18824	drug-related	_	
88-16	18825-18829	cues	_	
88-17	18830-18839	indicated	_	
88-18	18840-18849	increased	_	
88-19	18850-18862	reward-based	_	
88-20	18863-18872	cognitive	_	
88-21	18873-18882	processes	_	
88-22	18883-18885	in	_	
88-23	18886-18889	the	_	
88-24	18890-18898	presence	_	
88-25	18899-18901	of	_	
88-26	18902-18905	the	_	
88-27	18906-18910	cues	_	
88-28	18910-18911	.	_	

#Text=These studies disclosed that the caudate nucleus may be a crucial link between conditional and behavioral responses to procure drug and the DA activity responding to drug-related cues, which mediates the habitual nature of subjective experience of caving and compulsive drug-seeking behaviors in addicts.
89-1	18912-18917	These	_	
89-2	18918-18925	studies	_	
89-3	18926-18935	disclosed	_	
89-4	18936-18940	that	_	
89-5	18941-18944	the	_	
89-6	18945-18952	caudate	_	
89-7	18953-18960	nucleus	_	
89-8	18961-18964	may	_	
89-9	18965-18967	be	_	
89-10	18968-18969	a	_	
89-11	18970-18977	crucial	_	
89-12	18978-18982	link	_	
89-13	18983-18990	between	_	
89-14	18991-19002	conditional	_	
89-15	19003-19006	and	_	
89-16	19007-19017	behavioral	_	
89-17	19018-19027	responses	_	
89-18	19028-19030	to	_	
89-19	19031-19038	procure	_	
89-20	19039-19043	drug	_	
89-21	19044-19047	and	_	
89-22	19048-19051	the	_	
89-23	19052-19054	DA	_	
89-24	19055-19063	activity	_	
89-25	19064-19074	responding	_	
89-26	19075-19077	to	_	
89-27	19078-19090	drug-related	_	
89-28	19091-19095	cues	_	
89-29	19095-19096	,	_	
89-30	19097-19102	which	_	
89-31	19103-19111	mediates	_	
89-32	19112-19115	the	_	
89-33	19116-19124	habitual	_	
89-34	19125-19131	nature	_	
89-35	19132-19134	of	_	
89-36	19135-19145	subjective	_	
89-37	19146-19156	experience	_	
89-38	19157-19159	of	_	
89-39	19160-19166	caving	_	
89-40	19167-19170	and	_	
89-41	19171-19181	compulsive	_	
89-42	19182-19194	drug-seeking	_	
89-43	19195-19204	behaviors	_	
89-44	19205-19207	in	_	
89-45	19208-19215	addicts	_	
89-46	19215-19216	.	_	

#Text=In this study, we found that heroin relapsers’ ReHo values in right caudate were higher than non-relapsers, suggesting that relapsers had an abnormal reward response relative to the non-relapser even in the resting-sate.
90-1	19217-19219	In	_	
90-2	19220-19224	this	_	
90-3	19225-19230	study	_	
90-4	19230-19231	,	_	
90-5	19232-19234	we	_	
90-6	19235-19240	found	_	
90-7	19241-19245	that	_	
90-8	19246-19252	heroin	_	
90-9	19253-19262	relapsers	_	
90-10	19262-19263	’	_	
90-11	19264-19268	ReHo	_	
90-12	19269-19275	values	_	
90-13	19276-19278	in	_	
90-14	19279-19284	right	_	
90-15	19285-19292	caudate	_	
90-16	19293-19297	were	_	
90-17	19298-19304	higher	_	
90-18	19305-19309	than	_	
90-19	19310-19323	non-relapsers	_	
90-20	19323-19324	,	_	
90-21	19325-19335	suggesting	_	
90-22	19336-19340	that	_	
90-23	19341-19350	relapsers	_	
90-24	19351-19354	had	_	
90-25	19355-19357	an	_	
90-26	19358-19366	abnormal	_	
90-27	19367-19373	reward	_	
90-28	19374-19382	response	_	
90-29	19383-19391	relative	_	
90-30	19392-19394	to	_	
90-31	19395-19398	the	_	
90-32	19399-19411	non-relapser	_	
90-33	19412-19416	even	_	
90-34	19417-19419	in	_	
90-35	19420-19423	the	_	
90-36	19424-19436	resting-sate	_	
90-37	19436-19437	.	_	

#Text=Another area of the brain with increased ReHo in the present study was the cerebellum, which is reportedly involved in addictive behavior.
91-1	19438-19445	Another	_	
91-2	19446-19450	area	_	
91-3	19451-19453	of	_	
91-4	19454-19457	the	_	
91-5	19458-19463	brain	_	
91-6	19464-19468	with	_	
91-7	19469-19478	increased	_	
91-8	19479-19483	ReHo	_	
91-9	19484-19486	in	_	
91-10	19487-19490	the	_	
91-11	19491-19498	present	_	
91-12	19499-19504	study	_	
91-13	19505-19508	was	_	
91-14	19509-19512	the	_	
91-15	19513-19523	cerebellum	_	
91-16	19523-19524	,	_	
91-17	19525-19530	which	_	
91-18	19531-19533	is	_	
91-19	19534-19544	reportedly	_	
91-20	19545-19553	involved	_	
91-21	19554-19556	in	_	
91-22	19557-19566	addictive	_	
91-23	19567-19575	behavior	_	
91-24	19575-19576	.	_	

#Text=Previous PET and fMRI studies revealed that drug-conditioned cue could activate the cerebellum and increased its metabolism.
92-1	19577-19585	Previous	_	
92-2	19586-19589	PET	_	
92-3	19590-19593	and	_	
92-4	19594-19598	fMRI	_	
92-5	19599-19606	studies	_	
92-6	19607-19615	revealed	_	
92-7	19616-19620	that	_	
92-8	19621-19637	drug-conditioned	_	
92-9	19638-19641	cue	_	
92-10	19642-19647	could	_	
92-11	19648-19656	activate	_	
92-12	19657-19660	the	_	
92-13	19661-19671	cerebellum	_	
92-14	19672-19675	and	_	
92-15	19676-19685	increased	_	
92-16	19686-19689	its	_	
92-17	19690-19700	metabolism	_	
92-18	19700-19701	.	_	

#Text=When addicts performed reward expectation tasks, glucose metabolism in their cerebellum was greatly increased.
93-1	19702-19706	When	_	
93-2	19707-19714	addicts	_	
93-3	19715-19724	performed	_	
93-4	19725-19731	reward	_	
93-5	19732-19743	expectation	_	
93-6	19744-19749	tasks	_	
93-7	19749-19750	,	_	
93-8	19751-19758	glucose	_	
93-9	19759-19769	metabolism	_	
93-10	19770-19772	in	_	
93-11	19773-19778	their	_	
93-12	19779-19789	cerebellum	_	
93-13	19790-19793	was	_	
93-14	19794-19801	greatly	_	
93-15	19802-19811	increased	_	
93-16	19811-19812	.	_	

#Text=These results suggested the cerebellum was involved in drug-conditioned memories in addicts.
94-1	19813-19818	These	_	
94-2	19819-19826	results	_	
94-3	19827-19836	suggested	_	
94-4	19837-19840	the	_	
94-5	19841-19851	cerebellum	_	
94-6	19852-19855	was	_	
94-7	19856-19864	involved	_	
94-8	19865-19867	in	_	
94-9	19868-19884	drug-conditioned	_	
94-10	19885-19893	memories	_	
94-11	19894-19896	in	_	
94-12	19897-19904	addicts	_	
94-13	19904-19905	.	_	

#Text=Since cerebellum and caudate are the primary site of rewarding feeling, increased ReHo values in these areas in the relapsers under MMT probably indicated an abnormal enhancement of rewarding effect on heroin or heroin-related cues, leading to compulsive drug-seeking behaviors and ultimately increasing the possibility of heroin relapse.
95-1	19906-19911	Since	_	
95-2	19912-19922	cerebellum	_	
95-3	19923-19926	and	_	
95-4	19927-19934	caudate	_	
95-5	19935-19938	are	_	
95-6	19939-19942	the	_	
95-7	19943-19950	primary	_	
95-8	19951-19955	site	_	
95-9	19956-19958	of	_	
95-10	19959-19968	rewarding	_	
95-11	19969-19976	feeling	_	
95-12	19976-19977	,	_	
95-13	19978-19987	increased	_	
95-14	19988-19992	ReHo	_	
95-15	19993-19999	values	_	
95-16	20000-20002	in	_	
95-17	20003-20008	these	_	
95-18	20009-20014	areas	_	
95-19	20015-20017	in	_	
95-20	20018-20021	the	_	
95-21	20022-20031	relapsers	_	
95-22	20032-20037	under	_	
95-23	20038-20041	MMT	_	
95-24	20042-20050	probably	_	
95-25	20051-20060	indicated	_	
95-26	20061-20063	an	_	
95-27	20064-20072	abnormal	_	
95-28	20073-20084	enhancement	_	
95-29	20085-20087	of	_	
95-30	20088-20097	rewarding	_	
95-31	20098-20104	effect	_	
95-32	20105-20107	on	_	
95-33	20108-20114	heroin	_	
95-34	20115-20117	or	_	
95-35	20118-20132	heroin-related	_	
95-36	20133-20137	cues	_	
95-37	20137-20138	,	_	
95-38	20139-20146	leading	_	
95-39	20147-20149	to	_	
95-40	20150-20160	compulsive	_	
95-41	20161-20173	drug-seeking	_	
95-42	20174-20183	behaviors	_	
95-43	20184-20187	and	_	
95-44	20188-20198	ultimately	_	
95-45	20199-20209	increasing	_	
95-46	20210-20213	the	_	
95-47	20214-20225	possibility	_	
95-48	20226-20228	of	_	
95-49	20229-20235	heroin	_	
95-50	20236-20243	relapse	_	
95-51	20243-20244	.	_	

#Text=Additionally, cerebellum is also related to learning and memory, increased ReHo in cerebellum may result in abnormal enhancement of positive or negative emotions during drug addiction, which in this study, may induce the occurrence of heroin relapse behaviors.
96-1	20245-20257	Additionally	_	
96-2	20257-20258	,	_	
96-3	20259-20269	cerebellum	_	
96-4	20270-20272	is	_	
96-5	20273-20277	also	_	
96-6	20278-20285	related	_	
96-7	20286-20288	to	_	
96-8	20289-20297	learning	_	
96-9	20298-20301	and	_	
96-10	20302-20308	memory	_	
96-11	20308-20309	,	_	
96-12	20310-20319	increased	_	
96-13	20320-20324	ReHo	_	
96-14	20325-20327	in	_	
96-15	20328-20338	cerebellum	_	
96-16	20339-20342	may	_	
96-17	20343-20349	result	_	
96-18	20350-20352	in	_	
96-19	20353-20361	abnormal	_	
96-20	20362-20373	enhancement	_	
96-21	20374-20376	of	_	
96-22	20377-20385	positive	_	
96-23	20386-20388	or	_	
96-24	20389-20397	negative	_	
96-25	20398-20406	emotions	_	
96-26	20407-20413	during	_	
96-27	20414-20418	drug	_	
96-28	20419-20428	addiction	_	
96-29	20428-20429	,	_	
96-30	20430-20435	which	_	
96-31	20436-20438	in	_	
96-32	20439-20443	this	_	
96-33	20444-20449	study	_	
96-34	20449-20450	,	_	
96-35	20451-20454	may	_	
96-36	20455-20461	induce	_	
96-37	20462-20465	the	_	
96-38	20466-20476	occurrence	_	
96-39	20477-20479	of	_	
96-40	20480-20486	heroin	_	
96-41	20487-20494	relapse	_	
96-42	20495-20504	behaviors	_	
96-43	20504-20505	.	_	

#Text=In contrast, ReHo in several brain areas, especially in precuneus, were significantly decreased in heroin relapsers relative to non-relapsers.
97-1	20506-20508	In	_	
97-2	20509-20517	contrast	_	
97-3	20517-20518	,	_	
97-4	20519-20523	ReHo	_	
97-5	20524-20526	in	_	
97-6	20527-20534	several	_	
97-7	20535-20540	brain	_	
97-8	20541-20546	areas	_	
97-9	20546-20547	,	_	
97-10	20548-20558	especially	_	
97-11	20559-20561	in	_	
97-12	20562-20571	precuneus	_	
97-13	20571-20572	,	_	
97-14	20573-20577	were	_	
97-15	20578-20591	significantly	_	
97-16	20592-20601	decreased	_	
97-17	20602-20604	in	_	
97-18	20605-20611	heroin	_	
97-19	20612-20621	relapsers	_	
97-20	20622-20630	relative	_	
97-21	20631-20633	to	_	
97-22	20634-20647	non-relapsers	_	
97-23	20647-20648	.	_	

#Text=Apart from extension of the visuo-spatial processes subserved by the lateral parietal cortices, precuneus also plays an important role in a diverse array of highly integrated functions, e.g., involving in voluntary attention shifts between targets and playing a central role in the modulation of conscious process.
98-1	20649-20654	Apart	_	
98-2	20655-20659	from	_	
98-3	20660-20669	extension	_	
98-4	20670-20672	of	_	
98-5	20673-20676	the	_	
98-6	20677-20690	visuo-spatial	_	
98-7	20691-20700	processes	_	
98-8	20701-20710	subserved	_	
98-9	20711-20713	by	_	
98-10	20714-20717	the	_	
98-11	20718-20725	lateral	_	
98-12	20726-20734	parietal	_	
98-13	20735-20743	cortices	_	
98-14	20743-20744	,	_	
98-15	20745-20754	precuneus	_	
98-16	20755-20759	also	_	
98-17	20760-20765	plays	_	
98-18	20766-20768	an	_	
98-19	20769-20778	important	_	
98-20	20779-20783	role	_	
98-21	20784-20786	in	_	
98-22	20787-20788	a	_	
98-23	20789-20796	diverse	_	
98-24	20797-20802	array	_	
98-25	20803-20805	of	_	
98-26	20806-20812	highly	_	
98-27	20813-20823	integrated	_	
98-28	20824-20833	functions	_	
98-29	20833-20834	,	_	
98-30	20835-20838	e.g	_	
98-31	20838-20839	.	_	
98-32	20839-20840	,	_	
98-33	20841-20850	involving	_	
98-34	20851-20853	in	_	
98-35	20854-20863	voluntary	_	
98-36	20864-20873	attention	_	
98-37	20874-20880	shifts	_	
98-38	20881-20888	between	_	
98-39	20889-20896	targets	_	
98-40	20897-20900	and	_	
98-41	20901-20908	playing	_	
98-42	20909-20910	a	_	
98-43	20911-20918	central	_	
98-44	20919-20923	role	_	
98-45	20924-20926	in	_	
98-46	20927-20930	the	_	
98-47	20931-20941	modulation	_	
98-48	20942-20944	of	_	
98-49	20945-20954	conscious	_	
98-50	20955-20962	process	_	
98-51	20962-20963	.	_	

#Text=Precuneus could integrate information, which related to drug cues in the environment with the previously learned association involving those cues and relaying that information to the prefrontal cortex.
99-1	20964-20973	Precuneus	_	
99-2	20974-20979	could	_	
99-3	20980-20989	integrate	_	
99-4	20990-21001	information	_	
99-5	21001-21002	,	_	
99-6	21003-21008	which	_	
99-7	21009-21016	related	_	
99-8	21017-21019	to	_	
99-9	21020-21024	drug	_	
99-10	21025-21029	cues	_	
99-11	21030-21032	in	_	
99-12	21033-21036	the	_	
99-13	21037-21048	environment	_	
99-14	21049-21053	with	_	
99-15	21054-21057	the	_	
99-16	21058-21068	previously	_	
99-17	21069-21076	learned	_	
99-18	21077-21088	association	_	
99-19	21089-21098	involving	_	
99-20	21099-21104	those	_	
99-21	21105-21109	cues	_	
99-22	21110-21113	and	_	
99-23	21114-21122	relaying	_	
99-24	21123-21127	that	_	
99-25	21128-21139	information	_	
99-26	21140-21142	to	_	
99-27	21143-21146	the	_	
99-28	21147-21157	prefrontal	_	
99-29	21158-21164	cortex	_	
99-30	21164-21165	.	_	

#Text=We still lacked the knowledge about the decreased ReHo in precuneus of MMT relapsers.
100-1	21166-21168	We	_	
100-2	21169-21174	still	_	
100-3	21175-21181	lacked	_	
100-4	21182-21185	the	_	
100-5	21186-21195	knowledge	_	
100-6	21196-21201	about	_	
100-7	21202-21205	the	_	
100-8	21206-21215	decreased	_	
100-9	21216-21220	ReHo	_	
100-10	21221-21223	in	_	
100-11	21224-21233	precuneus	_	
100-12	21234-21236	of	_	
100-13	21237-21240	MMT	_	
100-14	21241-21250	relapsers	_	
100-15	21250-21251	.	_	

#Text=This may be associated with the destruction or clinical deficits of precuneus-related visual spatial attention and consciousness in heroin relapsers.
101-1	21252-21256	This	_	
101-2	21257-21260	may	_	
101-3	21261-21263	be	_	
101-4	21264-21274	associated	_	
101-5	21275-21279	with	_	
101-6	21280-21283	the	_	
101-7	21284-21295	destruction	_	
101-8	21296-21298	or	_	
101-9	21299-21307	clinical	_	
101-10	21308-21316	deficits	_	
101-11	21317-21319	of	_	
101-12	21320-21337	precuneus-related	_	
101-13	21338-21344	visual	_	
101-14	21345-21352	spatial	_	
101-15	21353-21362	attention	_	
101-16	21363-21366	and	_	
101-17	21367-21380	consciousness	_	
101-18	21381-21383	in	_	
101-19	21384-21390	heroin	_	
101-20	21391-21400	relapsers	_	
101-21	21400-21401	.	_	

#Text=Moreover, we observed a positive correlation between altered ReHo values in the right caudate and relapse rates or heroin craving.
102-1	21402-21410	Moreover	_	
102-2	21410-21411	,	_	
102-3	21412-21414	we	_	
102-4	21415-21423	observed	_	
102-5	21424-21425	a	_	
102-6	21426-21434	positive	_	
102-7	21435-21446	correlation	_	
102-8	21447-21454	between	_	
102-9	21455-21462	altered	_	
102-10	21463-21467	ReHo	_	
102-11	21468-21474	values	_	
102-12	21475-21477	in	_	
102-13	21478-21481	the	_	
102-14	21482-21487	right	_	
102-15	21488-21495	caudate	_	
102-16	21496-21499	and	_	
102-17	21500-21507	relapse	_	
102-18	21508-21513	rates	_	
102-19	21514-21516	or	_	
102-20	21517-21523	heroin	_	
102-21	21524-21531	craving	_	
102-22	21531-21532	.	_	

#Text=These findings support the idea that heroin relapse and craving were related to the caudate nucleus, which plays an important role in the habitual nature of subjective experience of caving and compulsive drug-seeking behaviors in drug addicts.
103-1	21533-21538	These	_	
103-2	21539-21547	findings	_	
103-3	21548-21555	support	_	
103-4	21556-21559	the	_	
103-5	21560-21564	idea	_	
103-6	21565-21569	that	_	
103-7	21570-21576	heroin	_	
103-8	21577-21584	relapse	_	
103-9	21585-21588	and	_	
103-10	21589-21596	craving	_	
103-11	21597-21601	were	_	
103-12	21602-21609	related	_	
103-13	21610-21612	to	_	
103-14	21613-21616	the	_	
103-15	21617-21624	caudate	_	
103-16	21625-21632	nucleus	_	
103-17	21632-21633	,	_	
103-18	21634-21639	which	_	
103-19	21640-21645	plays	_	
103-20	21646-21648	an	_	
103-21	21649-21658	important	_	
103-22	21659-21663	role	_	
103-23	21664-21666	in	_	
103-24	21667-21670	the	_	
103-25	21671-21679	habitual	_	
103-26	21680-21686	nature	_	
103-27	21687-21689	of	_	
103-28	21690-21700	subjective	_	
103-29	21701-21711	experience	_	
103-30	21712-21714	of	_	
103-31	21715-21721	caving	_	
103-32	21722-21725	and	_	
103-33	21726-21736	compulsive	_	
103-34	21737-21749	drug-seeking	_	
103-35	21750-21759	behaviors	_	
103-36	21760-21762	in	_	
103-37	21763-21767	drug	_	
103-38	21768-21775	addicts	_	
103-39	21775-21776	.	_	

#Text=Importantly, it also suggests that right caudate nucleus may not only serve as a reliable biomarker for predicting heroin relapse but also as a promising target for the treatment of MMT relapse.
104-1	21777-21788	Importantly	_	
104-2	21788-21789	,	_	
104-3	21790-21792	it	_	
104-4	21793-21797	also	_	
104-5	21798-21806	suggests	_	
104-6	21807-21811	that	_	
104-7	21812-21817	right	_	
104-8	21818-21825	caudate	_	
104-9	21826-21833	nucleus	_	
104-10	21834-21837	may	_	
104-11	21838-21841	not	_	
104-12	21842-21846	only	_	
104-13	21847-21852	serve	_	
104-14	21853-21855	as	_	
104-15	21856-21857	a	_	
104-16	21858-21866	reliable	_	
104-17	21867-21876	biomarker	_	
104-18	21877-21880	for	_	
104-19	21881-21891	predicting	_	
104-20	21892-21898	heroin	_	
104-21	21899-21906	relapse	_	
104-22	21907-21910	but	_	
104-23	21911-21915	also	_	
104-24	21916-21918	as	_	
104-25	21919-21920	a	_	
104-26	21921-21930	promising	_	
104-27	21931-21937	target	_	
104-28	21938-21941	for	_	
104-29	21942-21945	the	_	
104-30	21946-21955	treatment	_	
104-31	21956-21958	of	_	
104-32	21959-21962	MMT	_	
104-33	21963-21970	relapse	_	
104-34	21970-21971	.	_	

#Text=Admittedly, some limitations in the present are worth noting.
105-1	21972-21982	Admittedly	_	
105-2	21982-21983	,	_	
105-3	21984-21988	some	_	
105-4	21989-22000	limitations	_	
105-5	22001-22003	in	_	
105-6	22004-22007	the	_	
105-7	22008-22015	present	_	
105-8	22016-22019	are	_	
105-9	22020-22025	worth	_	
105-10	22026-22032	noting	_	
105-11	22032-22033	.	_	

#Text=First, in this study, female subjects were not included.
106-1	22034-22039	First	_	
106-2	22039-22040	,	_	
106-3	22041-22043	in	_	
106-4	22044-22048	this	_	
106-5	22049-22054	study	_	
106-6	22054-22055	,	_	
106-7	22056-22062	female	_	
106-8	22063-22071	subjects	_	
106-9	22072-22076	were	_	
106-10	22077-22080	not	_	
106-11	22081-22089	included	_	
106-12	22089-22090	.	_	

#Text=Thus, a possible gender difference in relapse susceptibility was unexplored.
107-1	22091-22095	Thus	_	
107-2	22095-22096	,	_	
107-3	22097-22098	a	_	
107-4	22099-22107	possible	_	
107-5	22108-22114	gender	_	
107-6	22115-22125	difference	_	
107-7	22126-22128	in	_	
107-8	22129-22136	relapse	_	
107-9	22137-22151	susceptibility	_	
107-10	22152-22155	was	_	
107-11	22156-22166	unexplored	_	
107-12	22166-22167	.	_	

#Text=Second, the interval of monthly self-report and urine test to assess MMT relapse was relatively long, probably not reflecting the true relapse rates.
108-1	22168-22174	Second	_	
108-2	22174-22175	,	_	
108-3	22176-22179	the	_	
108-4	22180-22188	interval	_	
108-5	22189-22191	of	_	
108-6	22192-22199	monthly	_	
108-7	22200-22211	self-report	_	
108-8	22212-22215	and	_	
108-9	22216-22221	urine	_	
108-10	22222-22226	test	_	
108-11	22227-22229	to	_	
108-12	22230-22236	assess	_	
108-13	22237-22240	MMT	_	
108-14	22241-22248	relapse	_	
108-15	22249-22252	was	_	
108-16	22253-22263	relatively	_	
108-17	22264-22268	long	_	
108-18	22268-22269	,	_	
108-19	22270-22278	probably	_	
108-20	22279-22282	not	_	
108-21	22283-22293	reflecting	_	
108-22	22294-22297	the	_	
108-23	22298-22302	true	_	
108-24	22303-22310	relapse	_	
108-25	22311-22316	rates	_	
108-26	22316-22317	.	_	

#Text=Finally, it had certain limitations by using urine test to assess the severity of MMT relapse.
109-1	22318-22325	Finally	_	
109-2	22325-22326	,	_	
109-3	22327-22329	it	_	
109-4	22330-22333	had	_	
109-5	22334-22341	certain	_	
109-6	22342-22353	limitations	_	
109-7	22354-22356	by	_	
109-8	22357-22362	using	_	
109-9	22363-22368	urine	_	
109-10	22369-22373	test	_	
109-11	22374-22376	to	_	
109-12	22377-22383	assess	_	
109-13	22384-22387	the	_	
109-14	22388-22396	severity	_	
109-15	22397-22399	of	_	
109-16	22400-22403	MMT	_	
109-17	22404-22411	relapse	_	
109-18	22411-22412	.	_	

#Text=In addition, in spite of the results obtained above, we still lacked the knowledge about which neural circuit played the crucial role in the relapse behavior in heroin addicts receiving MMT.
110-1	22413-22415	In	_	
110-2	22416-22424	addition	_	
110-3	22424-22425	,	_	
110-4	22426-22428	in	_	
110-5	22429-22434	spite	_	
110-6	22435-22437	of	_	
110-7	22438-22441	the	_	
110-8	22442-22449	results	_	
110-9	22450-22458	obtained	_	
110-10	22459-22464	above	_	
110-11	22464-22465	,	_	
110-12	22466-22468	we	_	
110-13	22469-22474	still	_	
110-14	22475-22481	lacked	_	
110-15	22482-22485	the	_	
110-16	22486-22495	knowledge	_	
110-17	22496-22501	about	_	
110-18	22502-22507	which	_	
110-19	22508-22514	neural	_	
110-20	22515-22522	circuit	_	
110-21	22523-22529	played	_	
110-22	22530-22533	the	_	
110-23	22534-22541	crucial	_	
110-24	22542-22546	role	_	
110-25	22547-22549	in	_	
110-26	22550-22553	the	_	
110-27	22554-22561	relapse	_	
110-28	22562-22570	behavior	_	
110-29	22571-22573	in	_	
110-30	22574-22580	heroin	_	
110-31	22581-22588	addicts	_	
110-32	22589-22598	receiving	_	
110-33	22599-22602	MMT	_	
110-34	22602-22603	.	_	

#Text=Therefore, other analysis methods such as fractional amplitude of low frequency fluctuations, degree of centrality maps, and the other metrics provided by resting-state fMRI should be employed to analyze the relationship of resting functional characteristics and relapse need further exploration.
111-1	22604-22613	Therefore	_	
111-2	22613-22614	,	_	
111-3	22615-22620	other	_	
111-4	22621-22629	analysis	_	
111-5	22630-22637	methods	_	
111-6	22638-22642	such	_	
111-7	22643-22645	as	_	
111-8	22646-22656	fractional	_	
111-9	22657-22666	amplitude	_	
111-10	22667-22669	of	_	
111-11	22670-22673	low	_	
111-12	22674-22683	frequency	_	
111-13	22684-22696	fluctuations	_	
111-14	22696-22697	,	_	
111-15	22698-22704	degree	_	
111-16	22705-22707	of	_	
111-17	22708-22718	centrality	_	
111-18	22719-22723	maps	_	
111-19	22723-22724	,	_	
111-20	22725-22728	and	_	
111-21	22729-22732	the	_	
111-22	22733-22738	other	_	
111-23	22739-22746	metrics	_	
111-24	22747-22755	provided	_	
111-25	22756-22758	by	_	
111-26	22759-22772	resting-state	_	
111-27	22773-22777	fMRI	_	
111-28	22778-22784	should	_	
111-29	22785-22787	be	_	
111-30	22788-22796	employed	_	
111-31	22797-22799	to	_	
111-32	22800-22807	analyze	_	
111-33	22808-22811	the	_	
111-34	22812-22824	relationship	_	
111-35	22825-22827	of	_	
111-36	22828-22835	resting	_	
111-37	22836-22846	functional	_	
111-38	22847-22862	characteristics	_	
111-39	22863-22866	and	_	
111-40	22867-22874	relapse	_	
111-41	22875-22879	need	_	
111-42	22880-22887	further	_	
111-43	22888-22899	exploration	_	
111-44	22899-22900	.	_	

#Text=Conclusion
#Text=In summary, compared with non-relapsers, heroin relapsers had an abnormal resting-state function.
112-1	22901-22911	Conclusion	_	
112-2	22912-22914	In	_	
112-3	22915-22922	summary	_	
112-4	22922-22923	,	_	
112-5	22924-22932	compared	_	
112-6	22933-22937	with	_	
112-7	22938-22951	non-relapsers	_	
112-8	22951-22952	,	_	
112-9	22953-22959	heroin	_	
112-10	22960-22969	relapsers	_	
112-11	22970-22973	had	_	
112-12	22974-22976	an	_	
112-13	22977-22985	abnormal	_	
112-14	22986-22999	resting-state	_	
112-15	23000-23008	function	_	
112-16	23008-23009	.	_	

#Text=Specially, relapsers displayed increased ReHo in the bilateral medial OFC, right caudate, and right cerebellum but decreased ReHo in the left parahippocampal gyrus, left middle temporal gyrus, right lingual gyrus, and precuneus.
113-1	23010-23019	Specially	_	
113-2	23019-23020	,	_	
113-3	23021-23030	relapsers	_	
113-4	23031-23040	displayed	_	
113-5	23041-23050	increased	_	
113-6	23051-23055	ReHo	_	
113-7	23056-23058	in	_	
113-8	23059-23062	the	_	
113-9	23063-23072	bilateral	_	
113-10	23073-23079	medial	_	
113-11	23080-23083	OFC	_	
113-12	23083-23084	,	_	
113-13	23085-23090	right	_	
113-14	23091-23098	caudate	_	
113-15	23098-23099	,	_	
113-16	23100-23103	and	_	
113-17	23104-23109	right	_	
113-18	23110-23120	cerebellum	_	
113-19	23121-23124	but	_	
113-20	23125-23134	decreased	_	
113-21	23135-23139	ReHo	_	
113-22	23140-23142	in	_	
113-23	23143-23146	the	_	
113-24	23147-23151	left	_	
113-25	23152-23167	parahippocampal	_	
113-26	23168-23173	gyrus	_	
113-27	23173-23174	,	_	
113-28	23175-23179	left	_	
113-29	23180-23186	middle	_	
113-30	23187-23195	temporal	_	
113-31	23196-23201	gyrus	_	
113-32	23201-23202	,	_	
113-33	23203-23208	right	_	
113-34	23209-23216	lingual	_	
113-35	23217-23222	gyrus	_	
113-36	23222-23223	,	_	
113-37	23224-23227	and	_	
113-38	23228-23237	precuneus	_	
113-39	23237-23238	.	_	

#Text=The alterations of ReHo in these areas may involve abnormal motivation, reward, memory and visual spatial attention.
114-1	23239-23242	The	_	
114-2	23243-23254	alterations	_	
114-3	23255-23257	of	_	
114-4	23258-23262	ReHo	_	
114-5	23263-23265	in	_	
114-6	23266-23271	these	_	
114-7	23272-23277	areas	_	
114-8	23278-23281	may	_	
114-9	23282-23289	involve	_	
114-10	23290-23298	abnormal	_	
114-11	23299-23309	motivation	_	
114-12	23309-23310	,	_	
114-13	23311-23317	reward	_	
114-14	23317-23318	,	_	
114-15	23319-23325	memory	_	
114-16	23326-23329	and	_	
114-17	23330-23336	visual	_	
114-18	23337-23344	spatial	_	
114-19	23345-23354	attention	_	
114-20	23354-23355	.	_	

#Text=Overall, our results may add to neurobiological factors associated with relapse to heroin use and also be conducive to developing a promising strategy for heroin addiction therapies.
115-1	23356-23363	Overall	_	
115-2	23363-23364	,	_	
115-3	23365-23368	our	_	
115-4	23369-23376	results	_	
115-5	23377-23380	may	_	
115-6	23381-23384	add	_	
115-7	23385-23387	to	_	
115-8	23388-23403	neurobiological	_	
115-9	23404-23411	factors	_	
115-10	23412-23422	associated	_	
115-11	23423-23427	with	_	
115-12	23428-23435	relapse	_	
115-13	23436-23438	to	_	
115-14	23439-23445	heroin	_	
115-15	23446-23449	use	_	
115-16	23450-23453	and	_	
115-17	23454-23458	also	_	
115-18	23459-23461	be	_	
115-19	23462-23471	conducive	_	
115-20	23472-23474	to	_	
115-21	23475-23485	developing	_	
115-22	23486-23487	a	_	
115-23	23488-23497	promising	_	
115-24	23498-23506	strategy	_	
115-25	23507-23510	for	_	
115-26	23511-23517	heroin	_	
115-27	23518-23527	addiction	_	
115-28	23528-23537	therapies	_	
115-29	23537-23538	.	_	

#Text=Abbreviations
#Text=MMT, methadone maintenance treatment; OFC, orbitofrontal cortex; ReHo, regional homogeneity; VAS, visual analogue scale
#Text=References
#Text=Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex
#Text=Opiate addiction in China: current situation and treatments
#Text=A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts
#Text=Methadone maintenance treatment (MMT): a review of historical and clinical issues
#Text=Addiction: beyond dopamine reward circuitry
#Text=Addiction related alteration in resting-state brain connectivity
#Text=Dysfunctional connectivity patterns in chronic heroin users: an fMRI study
#Text=Regional homogeneity approach to fMRI data analysis
#Text=Normal aging decreases regional homogeneity of the motor areas in the resting state
#Text=Regional coherence changes in the early stages of Alzheimer's disease: a combined structural and resting-state functional MRI study
#Text=Regional homogeneity changes in patients with Parkinson's disease
#Text=Decreased regional homogeneity in schizophrenia: a resting state functional magnetic resonance imaging study
#Text=Regional homogeneity changes in patients with neuromyelitis optica revealed by resting-state functional MRI
#Text=Regional homogeneity changes in heroin-dependent individuals: resting-state functional MR imaging study
#Text=The assessment and analysis of handedness: the Edinburgh inventory
#Text=Biological correlates of mental activity studied with PET
#Text=Limbic responsiveness to procaine in cocaine-addicted subjects
#Text=Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex
#Text=The addicted human brain: insights from imaging studies
#Text=Neural activity associated with cognitive regulation in heroin users: A fMRI study
#Text=The orbitofrontal cortex and reward
#Text=Roles for nigrostriatal--not just mesocorticolimbic--dopamine in reward and addiction
#Text=Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction
#Text=Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study
#Text=Practice-related functional activation changes in a working memory task
#Text=A neural correlate of reward-based behavioral learning in caudate nucleus: a functional magnetic resonance imaging study of a stochastic decision task
#Text=Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum
#Text=Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum
#Text=Activation of memory circuits during cue-elicited cocaine craving
#Text=Regional brain metabolic activation during craving elicited by recall of previous drug experiences
#Text=Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers
#Text=The precuneus: a review of its functional anatomy and behavioural correlates
#Text=Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies
116-1	23539-23552	Abbreviations	_	
116-2	23553-23556	MMT	_	
116-3	23556-23557	,	_	
116-4	23558-23567	methadone	_	
116-5	23568-23579	maintenance	_	
116-6	23580-23589	treatment	_	
116-7	23589-23590	;	_	
116-8	23591-23594	OFC	_	
116-9	23594-23595	,	_	
116-10	23596-23609	orbitofrontal	_	
116-11	23610-23616	cortex	_	
116-12	23616-23617	;	_	
116-13	23618-23622	ReHo	_	
116-14	23622-23623	,	_	
116-15	23624-23632	regional	_	
116-16	23633-23644	homogeneity	_	
116-17	23644-23645	;	_	
116-18	23646-23649	VAS	_	
116-19	23649-23650	,	_	
116-20	23651-23657	visual	_	
116-21	23658-23666	analogue	_	
116-22	23667-23672	scale	_	
116-23	23673-23683	References	_	
116-24	23684-23688	Drug	_	
116-25	23689-23698	addiction	_	
116-26	23699-23702	and	_	
116-27	23703-23706	its	_	
116-28	23707-23717	underlying	_	
116-29	23718-23733	neurobiological	_	
116-30	23734-23739	basis	_	
116-31	23739-23740	:	_	
116-32	23741-23753	neuroimaging	_	
116-33	23754-23762	evidence	_	
116-34	23763-23766	for	_	
116-35	23767-23770	the	_	
116-36	23771-23782	involvement	_	
116-37	23783-23785	of	_	
116-38	23786-23789	the	_	
116-39	23790-23797	frontal	_	
116-40	23798-23804	cortex	_	
116-41	23805-23811	Opiate	_	
116-42	23812-23821	addiction	_	
116-43	23822-23824	in	_	
116-44	23825-23830	China	_	
116-45	23830-23831	:	_	
116-46	23832-23839	current	_	
116-47	23840-23849	situation	_	
116-48	23850-23853	and	_	
116-49	23854-23864	treatments	_	
116-50	23865-23866	A	_	
116-51	23867-23878	comparative	_	
116-52	23879-23884	study	_	
116-53	23885-23887	of	_	
116-54	23888-23901	physiological	_	
116-55	23902-23905	and	_	
116-56	23906-23916	subjective	_	
116-57	23917-23924	effects	_	
116-58	23925-23927	of	_	
116-59	23928-23934	heroin	_	
116-60	23935-23938	and	_	
116-61	23939-23947	morphine	_	
116-62	23948-23960	administered	_	
116-63	23961-23974	intravenously	_	
116-64	23975-23977	in	_	
116-65	23978-23989	postaddicts	_	
116-66	23990-23999	Methadone	_	
116-67	24000-24011	maintenance	_	
116-68	24012-24021	treatment	_	
116-69	24022-24023	(	_	
116-70	24023-24026	MMT	_	
116-71	24026-24027	)	_	
116-72	24027-24028	:	_	
116-73	24029-24030	a	_	
116-74	24031-24037	review	_	
116-75	24038-24040	of	_	
116-76	24041-24051	historical	_	
116-77	24052-24055	and	_	
116-78	24056-24064	clinical	_	
116-79	24065-24071	issues	_	
116-80	24072-24081	Addiction	_	
116-81	24081-24082	:	_	
116-82	24083-24089	beyond	_	
116-83	24090-24098	dopamine	_	
116-84	24099-24105	reward	_	
116-85	24106-24115	circuitry	_	
116-86	24116-24125	Addiction	_	
116-87	24126-24133	related	_	
116-88	24134-24144	alteration	_	
116-89	24145-24147	in	_	
116-90	24148-24161	resting-state	_	
116-91	24162-24167	brain	_	
116-92	24168-24180	connectivity	_	
116-93	24181-24194	Dysfunctional	_	
116-94	24195-24207	connectivity	_	
116-95	24208-24216	patterns	_	
116-96	24217-24219	in	_	
116-97	24220-24227	chronic	_	
116-98	24228-24234	heroin	_	
116-99	24235-24240	users	_	
116-100	24240-24241	:	_	
116-101	24242-24244	an	_	
116-102	24245-24249	fMRI	_	
116-103	24250-24255	study	_	
116-104	24256-24264	Regional	_	
116-105	24265-24276	homogeneity	_	
116-106	24277-24285	approach	_	
116-107	24286-24288	to	_	
116-108	24289-24293	fMRI	_	
116-109	24294-24298	data	_	
116-110	24299-24307	analysis	_	
116-111	24308-24314	Normal	_	
116-112	24315-24320	aging	_	
116-113	24321-24330	decreases	_	
116-114	24331-24339	regional	_	
116-115	24340-24351	homogeneity	_	
116-116	24352-24354	of	_	
116-117	24355-24358	the	_	
116-118	24359-24364	motor	_	
116-119	24365-24370	areas	_	
116-120	24371-24373	in	_	
116-121	24374-24377	the	_	
116-122	24378-24385	resting	_	
116-123	24386-24391	state	_	
116-124	24392-24400	Regional	_	
116-125	24401-24410	coherence	_	
116-126	24411-24418	changes	_	
116-127	24419-24421	in	_	
116-128	24422-24425	the	_	
116-129	24426-24431	early	_	
116-130	24432-24438	stages	_	
116-131	24439-24441	of	_	
116-132	24442-24453	Alzheimer's	_	
116-133	24454-24461	disease	_	
116-134	24461-24462	:	_	
116-135	24463-24464	a	_	
116-136	24465-24473	combined	_	
116-137	24474-24484	structural	_	
116-138	24485-24488	and	_	
116-139	24489-24502	resting-state	_	
116-140	24503-24513	functional	_	
116-141	24514-24517	MRI	_	
116-142	24518-24523	study	_	
116-143	24524-24532	Regional	_	
116-144	24533-24544	homogeneity	_	
116-145	24545-24552	changes	_	
116-146	24553-24555	in	_	
116-147	24556-24564	patients	_	
116-148	24565-24569	with	_	
116-149	24570-24581	Parkinson's	_	
116-150	24582-24589	disease	_	
116-151	24590-24599	Decreased	_	
116-152	24600-24608	regional	_	
116-153	24609-24620	homogeneity	_	
116-154	24621-24623	in	_	
116-155	24624-24637	schizophrenia	_	
116-156	24637-24638	:	_	
116-157	24639-24640	a	_	
116-158	24641-24648	resting	_	
116-159	24649-24654	state	_	
116-160	24655-24665	functional	_	
116-161	24666-24674	magnetic	_	
116-162	24675-24684	resonance	_	
116-163	24685-24692	imaging	_	
116-164	24693-24698	study	_	
116-165	24699-24707	Regional	_	
116-166	24708-24719	homogeneity	_	
116-167	24720-24727	changes	_	
116-168	24728-24730	in	_	
116-169	24731-24739	patients	_	
116-170	24740-24744	with	_	
116-171	24745-24758	neuromyelitis	_	
116-172	24759-24765	optica	_	
116-173	24766-24774	revealed	_	
116-174	24775-24777	by	_	
116-175	24778-24791	resting-state	_	
116-176	24792-24802	functional	_	
116-177	24803-24806	MRI	_	
116-178	24807-24815	Regional	_	
116-179	24816-24827	homogeneity	_	
116-180	24828-24835	changes	_	
116-181	24836-24838	in	_	
116-182	24839-24855	heroin-dependent	_	
116-183	24856-24867	individuals	_	
116-184	24867-24868	:	_	
116-185	24869-24882	resting-state	_	
116-186	24883-24893	functional	_	
116-187	24894-24896	MR	_	
116-188	24897-24904	imaging	_	
116-189	24905-24910	study	_	
116-190	24911-24914	The	_	
116-191	24915-24925	assessment	_	
116-192	24926-24929	and	_	
116-193	24930-24938	analysis	_	
116-194	24939-24941	of	_	
116-195	24942-24952	handedness	_	
116-196	24952-24953	:	_	
116-197	24954-24957	the	_	
116-198	24958-24967	Edinburgh	_	
116-199	24968-24977	inventory	_	
116-200	24978-24988	Biological	_	
116-201	24989-24999	correlates	_	
116-202	25000-25002	of	_	
116-203	25003-25009	mental	_	
116-204	25010-25018	activity	_	
116-205	25019-25026	studied	_	
116-206	25027-25031	with	_	
116-207	25032-25035	PET	_	
116-208	25036-25042	Limbic	_	
116-209	25043-25057	responsiveness	_	
116-210	25058-25060	to	_	
116-211	25061-25069	procaine	_	
116-212	25070-25072	in	_	
116-213	25073-25089	cocaine-addicted	_	
116-214	25090-25098	subjects	_	
116-215	25099-25108	Addiction	_	
116-216	25108-25109	,	_	
116-217	25110-25111	a	_	
116-218	25112-25119	disease	_	
116-219	25120-25122	of	_	
116-220	25123-25133	compulsion	_	
116-221	25134-25137	and	_	
116-222	25138-25143	drive	_	
116-223	25143-25144	:	_	
116-224	25145-25156	involvement	_	
116-225	25157-25159	of	_	
116-226	25160-25163	the	_	
116-227	25164-25177	orbitofrontal	_	
116-228	25178-25184	cortex	_	
116-229	25185-25188	The	_	
116-230	25189-25197	addicted	_	
116-231	25198-25203	human	_	
116-232	25204-25209	brain	_	
116-233	25209-25210	:	_	
116-234	25211-25219	insights	_	
116-235	25220-25224	from	_	
116-236	25225-25232	imaging	_	
116-237	25233-25240	studies	_	
116-238	25241-25247	Neural	_	
116-239	25248-25256	activity	_	
116-240	25257-25267	associated	_	
116-241	25268-25272	with	_	
116-242	25273-25282	cognitive	_	
116-243	25283-25293	regulation	_	
116-244	25294-25296	in	_	
116-245	25297-25303	heroin	_	
116-246	25304-25309	users	_	
116-247	25309-25310	:	_	
116-248	25311-25312	A	_	
116-249	25313-25317	fMRI	_	
116-250	25318-25323	study	_	
116-251	25324-25327	The	_	
116-252	25328-25341	orbitofrontal	_	
116-253	25342-25348	cortex	_	
116-254	25349-25352	and	_	
116-255	25353-25359	reward	_	
116-256	25360-25365	Roles	_	
116-257	25366-25369	for	_	
116-258	25370-25383	nigrostriatal	_	
116-259	25383-25384	-	_	
116-260	25384-25385	-	_	
116-261	25385-25388	not	_	
116-262	25389-25393	just	_	
116-263	25394-25411	mesocorticolimbic	_	
116-264	25411-25412	-	_	
116-265	25412-25413	-	_	
116-266	25413-25421	dopamine	_	
116-267	25422-25424	in	_	
116-268	25425-25431	reward	_	
116-269	25432-25435	and	_	
116-270	25436-25445	addiction	_	
116-271	25446-25453	Cocaine	_	
116-272	25454-25458	cues	_	
116-273	25459-25462	and	_	
116-274	25463-25471	dopamine	_	
116-275	25472-25474	in	_	
116-276	25475-25481	dorsal	_	
116-277	25482-25490	striatum	_	
116-278	25490-25491	:	_	
116-279	25492-25501	mechanism	_	
116-280	25502-25504	of	_	
116-281	25505-25512	craving	_	
116-282	25513-25515	in	_	
116-283	25516-25523	cocaine	_	
116-284	25524-25533	addiction	_	
116-285	25534-25540	Neural	_	
116-286	25541-25549	activity	_	
116-287	25550-25560	associated	_	
116-288	25561-25565	with	_	
116-289	25566-25580	stress-induced	_	
116-290	25581-25588	cocaine	_	
116-291	25589-25596	craving	_	
116-292	25596-25597	:	_	
116-293	25598-25599	a	_	
116-294	25600-25610	functional	_	
116-295	25611-25619	magnetic	_	
116-296	25620-25629	resonance	_	
116-297	25630-25637	imaging	_	
116-298	25638-25643	study	_	
116-299	25644-25660	Practice-related	_	
116-300	25661-25671	functional	_	
116-301	25672-25682	activation	_	
116-302	25683-25690	changes	_	
116-303	25691-25693	in	_	
116-304	25694-25695	a	_	
116-305	25696-25703	working	_	
116-306	25704-25710	memory	_	
116-307	25711-25715	task	_	
116-308	25716-25717	A	_	
116-309	25718-25724	neural	_	
116-310	25725-25734	correlate	_	
116-311	25735-25737	of	_	
116-312	25738-25750	reward-based	_	
116-313	25751-25761	behavioral	_	
116-314	25762-25770	learning	_	
116-315	25771-25773	in	_	
116-316	25774-25781	caudate	_	
116-317	25782-25789	nucleus	_	
116-318	25789-25790	:	_	
116-319	25791-25792	a	_	
116-320	25793-25803	functional	_	
116-321	25804-25812	magnetic	_	
116-322	25813-25822	resonance	_	
116-323	25823-25830	imaging	_	
116-324	25831-25836	study	_	
116-325	25837-25839	of	_	
116-326	25840-25841	a	_	
116-327	25842-25852	stochastic	_	
116-328	25853-25861	decision	_	
116-329	25862-25866	task	_	
116-330	25867-25874	Initial	_	
116-331	25874-25875	,	_	
116-332	25876-25884	habitual	_	
116-333	25885-25888	and	_	
116-334	25889-25899	compulsive	_	
116-335	25900-25907	alcohol	_	
116-336	25908-25911	use	_	
116-337	25912-25914	is	_	
116-338	25915-25928	characterized	_	
116-339	25929-25931	by	_	
116-340	25932-25933	a	_	
116-341	25934-25939	shift	_	
116-342	25940-25942	of	_	
116-343	25943-25946	cue	_	
116-344	25947-25957	processing	_	
116-345	25958-25962	from	_	
116-346	25963-25970	ventral	_	
116-347	25971-25973	to	_	
116-348	25974-25980	dorsal	_	
116-349	25981-25989	striatum	_	
116-350	25990-25997	Cocaine	_	
116-351	25998-26005	seeking	_	
116-352	26006-26012	habits	_	
116-353	26013-26019	depend	_	
116-354	26020-26024	upon	_	
116-355	26025-26043	dopamine-dependent	_	
116-356	26044-26050	serial	_	
116-357	26051-26063	connectivity	_	
116-358	26064-26071	linking	_	
116-359	26072-26075	the	_	
116-360	26076-26083	ventral	_	
116-361	26084-26088	with	_	
116-362	26089-26092	the	_	
116-363	26093-26099	dorsal	_	
116-364	26100-26108	striatum	_	
116-365	26109-26119	Activation	_	
116-366	26120-26122	of	_	
116-367	26123-26129	memory	_	
116-368	26130-26138	circuits	_	
116-369	26139-26145	during	_	
116-370	26146-26158	cue-elicited	_	
116-371	26159-26166	cocaine	_	
116-372	26167-26174	craving	_	
116-373	26175-26183	Regional	_	
116-374	26184-26189	brain	_	
116-375	26190-26199	metabolic	_	
116-376	26200-26210	activation	_	
116-377	26211-26217	during	_	
116-378	26218-26225	craving	_	
116-379	26226-26234	elicited	_	
116-380	26235-26237	by	_	
116-381	26238-26244	recall	_	
116-382	26245-26247	of	_	
116-383	26248-26256	previous	_	
116-384	26257-26261	drug	_	
116-385	26262-26273	experiences	_	
116-386	26274-26285	Expectation	_	
116-387	26286-26294	enhances	_	
116-388	26295-26298	the	_	
116-389	26299-26307	regional	_	
116-390	26308-26313	brain	_	
116-391	26314-26323	metabolic	_	
116-392	26324-26327	and	_	
116-393	26328-26331	the	_	
116-394	26332-26343	reinforcing	_	
116-395	26344-26351	effects	_	
116-396	26352-26354	of	_	
116-397	26355-26365	stimulants	_	
116-398	26366-26368	in	_	
116-399	26369-26376	cocaine	_	
116-400	26377-26384	abusers	_	
116-401	26385-26388	The	_	
116-402	26389-26398	precuneus	_	
116-403	26398-26399	:	_	
116-404	26400-26401	a	_	
116-405	26402-26408	review	_	
116-406	26409-26411	of	_	
116-407	26412-26415	its	_	
116-408	26416-26426	functional	_	
116-409	26427-26434	anatomy	_	
116-410	26435-26438	and	_	
116-411	26439-26450	behavioural	_	
116-412	26451-26461	correlates	_	
116-413	26462-26468	Neural	_	
116-414	26469-26479	substrates	_	
116-415	26480-26482	of	_	
116-416	26483-26490	smoking	_	
116-417	26491-26494	cue	_	
116-418	26495-26505	reactivity	_	
116-419	26505-26506	:	_	
116-420	26507-26508	a	_	
116-421	26509-26522	meta-analysis	_	
116-422	26523-26525	of	_	
116-423	26526-26530	fMRI	_	
116-424	26531-26538	studies	_	
